Team
Bruno ségui – nathalie andrieu
MELASPHINX :
Ceramide metabolism in melanoma: from basic mechanisms to immunotherapy
General presentation of the team
Our team was created in 2011, under the direction of Prof. Thierry Levade. Since 2021, it has been led by Prof. Bruno Ségui and Dr. Nathalie Andrieu-Abadie. It is composed of 26 members, including 3 researchers, 2 assistant professors, 4 professors, 5 engineers/technicians, 2 hospital practitioners, 2 post-doctoral fellows, 5 PhD students and 3 master trainees per year.
Scientific objectives
Cutaneous melanoma is the leading cause of death among skin cancers. Immune checkpoint inhibitors (ICI) have revolutionised the therapeutic management of patients with advanced cutaneous melanoma. However, only half of patients respond sustainably to ICIs due to primary or adaptive resistance mechanisms. Abnormal lipid profiles are often associated with an altered metabolic phenotype in tumour cells, which is a hallmark of cancer. The scientific activity of our team aims to better understand the molecular mechanisms by which alterations in ceramide metabolism contribute to melanoma progression, immune escape and resistance to ICI in preclinical models of melanoma. Through existing collaborations between researchers and clinicians, our ambition is to transfer our basic scientific findings to the clinic with the aim of identifying new biomarkers to predict response to ICIs and to propose appropriate treatments for patients with advanced melanoma. In addition, our research over the past 5 years has provided the scientific rationale for three clinical trials in 150 patients with advanced melanoma treated with immunotherapy. These trials are under the responsibility of Prof. Nicolas Meyer, oncodermatologist at the IUCT.
Our ultimate goal is to reprogram the metabolism of ceramide to improve therapeutic efficacy.
The specificities
of our research axis
Melanoma
Metabolism
Ceramide
Immunotherapy
TNF
Research
projects
Role of ceramide metabolism in epidermal homeostasis and melanoma progression
Nathalie Andrieu
Associate investigators : Joëlle Riond et Frédérique Sabourdy
Interconnections between TNF signalling and ceramide metabolism in melanoma
Bruno Ségui
Associate investigators : Nathalie Andrieu, Céline Colacios, Anne Montfort
Reprogramming ceramide metabolism to overcome resistance to immunotherapies
Céline Colacios, Anne Montfort
Associate investigators : Nathalie Andrieu, Thierry Levade, Laurence Nieto
Metabolites and enzymes of ceramide metabolism as biomarkers of resistance to immunotherapies?
Nicolas Meyer
Associate investigators : Nathalie Andrieu, Céline Colacios, Anne Montfort et Bruno Ségui
TNF, a new target for immunotherapy ?
Nicolas Meyer
Associate investigators : Anne Montfort et Bruno Ségui
THE TEAM’S
FOCUS
Discover
Understand
Participate
live
;
Merci à la ligue contre le cancer de la Haute-Garonne pour son soutien au projet porté par le Pr Colacios dans le cancer du sein triple négatif #tnbc @crctoncopole @IUCTOncopole
Merci à Céline Colacios, enseignante et chercheur au CRCT de Toulouse pour ce partage de connaissances sur le #cancerdusein triple négatif.
Nous sommes très attentifs au fait de financer des projets permettant des avancées cruciales pour la compréhension de ce type de cancer.
Scientific productions
PUBLICATIONS 2025
7813506
KC3WFBJR
2025
1
chicago-fullnote-bibliography
50
date
desc
42676
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22Z37VSVHE%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Villeneuve%20et%20al.%22%2C%22parsedDate%22%3A%222025-11-25%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BVilleneuve%2C%20Thomas%2C%20Thibaut%20Jamme%2C%20Robin%20Schwob%2C%20Thierry%20Levade%2C%20and%20Gr%26%23xE9%3Bgoire%20Pr%26%23xE9%3Bvot.%20%26%23x201C%3BCorrection%3A%20Advanced%20Strategies%20for%20Detecting%20Acid%20Sphingomyelinase%20Deficiency%20Type%20B%20with%20Attenuated%20Phenotypes.%26%23x201D%3B%20%26lt%3Bi%26gt%3BOrphanet%20Journal%20of%20Rare%20Diseases%26lt%3B%5C%2Fi%26gt%3B%2020%2C%20no.%201%20%28November%2025%2C%202025%29%3A%20604.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13023-025-03996-7%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13023-025-03996-7%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Correction%3A%20Advanced%20strategies%20for%20detecting%20acid%20sphingomyelinase%20deficiency%20type%20B%20with%20attenuated%20phenotypes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Villeneuve%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaut%22%2C%22lastName%22%3A%22Jamme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robin%22%2C%22lastName%22%3A%22Schwob%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gr%5Cu00e9goire%22%2C%22lastName%22%3A%22Pr%5Cu00e9vot%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222025-11-25%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs13023-025-03996-7%22%2C%22ISSN%22%3A%221750-1172%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222025-12-01T08%3A33%3A40Z%22%7D%7D%2C%7B%22key%22%3A%228P86DX4P%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Xu%20et%20al.%22%2C%22parsedDate%22%3A%222025-08-15%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BXu%2C%20TianMeng%2C%20Rachel%20Heon-Roberts%2C%20Travis%20Moore%2C%20Patricia%20Dubot%2C%20Xuefang%20Pan%2C%20Tianlin%20Guo%2C%20Christopher%20W.%20Cairo%2C%20et%20al.%20%26%23x201C%3BNeuraminidase%201%20Secondary%20Deficiency%20Contributes%20to%20CNS%20Pathology%20in%20Neurological%20Mucopolysaccharidoses%20via%20Brain%20Protein%20Hypersialylation.%26%23x201D%3B%20%26lt%3Bi%26gt%3BThe%20Journal%20of%20Clinical%20Investigation%26lt%3B%5C%2Fi%26gt%3B%20135%2C%20no.%2016%20%28August%2015%2C%202025%29%3A%20e177430.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1172%5C%2FJCI177430%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1172%5C%2FJCI177430%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Neuraminidase%201%20secondary%20deficiency%20contributes%20to%20CNS%20pathology%20in%20neurological%20mucopolysaccharidoses%20via%20brain%20protein%20hypersialylation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22TianMeng%22%2C%22lastName%22%3A%22Xu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%22%2C%22lastName%22%3A%22Heon-Roberts%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Travis%22%2C%22lastName%22%3A%22Moore%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Dubot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xuefang%22%2C%22lastName%22%3A%22Pan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tianlin%22%2C%22lastName%22%3A%22Guo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20W.%22%2C%22lastName%22%3A%22Cairo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rebecca%20J.%22%2C%22lastName%22%3A%22Holley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%22%2C%22lastName%22%3A%22Bigger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20M.%22%2C%22lastName%22%3A%22Durcan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jer%5Cu00f4me%22%2C%22lastName%22%3A%22Ausseil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9n%5Cu00e9dicte%22%2C%22lastName%22%3A%22Amilhon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexei%22%2C%22lastName%22%3A%22Gorelik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bhushan%22%2C%22lastName%22%3A%22Nagar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaukat%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shunji%22%2C%22lastName%22%3A%22Tomatsu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luisa%22%2C%22lastName%22%3A%22Sturiale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angelo%22%2C%22lastName%22%3A%22Palmigiano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Iris%22%2C%22lastName%22%3A%22R%5Cu00f6ckle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hauke%22%2C%22lastName%22%3A%22Thiesler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herbert%22%2C%22lastName%22%3A%22Hildebrandt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Domenico%22%2C%22lastName%22%3A%22Garozzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexey%20V.%22%2C%22lastName%22%3A%22Pshezhetsky%22%7D%5D%2C%22abstractNote%22%3A%22Mucopolysaccharidoses%20%28MPS%29%20are%20lysosomal%20storage%20diseases%20caused%20by%20defects%20in%20catabolism%20of%20glycosaminoglycans.%20MPS%20I%2C%20II%2C%20III%2C%20and%20VII%2C%20which%20are%20associated%20with%20lysosomal%20accumulation%20of%20heparan%20sulphate%20%28HS%29%2C%20manifest%20with%20neurological%20deterioration%20and%20currently%20lack%20effective%20treatments.%20We%20report%20that%20neuraminidase%201%20%28NEU1%29%20activity%20is%20drastically%20reduced%20in%20brain%20tissues%20of%20patients%20with%20neurological%20MPS%20and%20mouse%20models%20but%20not%20in%20neurological%20lysosomal%20disorders%20without%20HS%20storage.%20Accumulated%20HS%20disrupts%20the%20lysosomal%20multienzyme%20complex%20of%20NEU1%20with%20cathepsin%20A%2C%20%5Cu03b2-galactosidase%20%28GLB1%29%2C%20and%20glucosamine-6-sulfate%20sulfatase%20%28GALNS%29%2C%20leading%20to%20NEU1%20deficiency%20and%20partial%20GLB1%20and%20GALNS%20deficiencies%20in%20cortical%20tissues%20and%20induced%20pluripotent%20stem%20cell-derived%20%28iPSC-derived%29%20cortical%20neurons%20of%20patients%20with%20neurological%20MPS.%20Increased%20sialylation%20of%20N-linked%20glycans%20in%20brains%20of%20patients%20with%20MPS%20and%20mice%20implicated%20insufficient%20processing%20of%20sialylated%20glycans%2C%20except%20for%20polysialic%20acid.%20Correction%20of%20NEU1%20activity%20in%20MPS%20IIIC%20mice%20by%20lentiviral%20%28LV%29%20gene%20transfer%20ameliorated%20previously%20identified%20hallmarks%20of%20the%20disease%2C%20including%20memory%20impairment%2C%20behavioral%20traits%2C%20and%20reduced%20levels%20of%20excitatory%20synapse%20markers%20VGLUT1%20and%20PSD95.%20Overexpression%20of%20NEU1%20also%20restored%20levels%20of%20VGLUT1%5C%2FPSD95-positive%20puncta%20in%20cortical%20iPSC-derived%20MPS%20IIIA%20neurons.%20Our%20results%20demonstrate%20that%20HS-induced%20secondary%20NEU1%20deficiency%20and%20aberrant%20sialylation%20of%20brain%20glycoproteins%20constitute%20what%20we%20believe%20is%20a%20novel%20pathological%20pathway%20in%20the%20neurological%20MPS%20spectrum%20crucially%20contributing%20to%20CNS%20pathology.%22%2C%22date%22%3A%222025-08-15%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1172%5C%2FJCI177430%22%2C%22ISSN%22%3A%221558-8238%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222025-09-03T14%3A32%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22NL7X8FZ6%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Villeneuve%20et%20al.%22%2C%22parsedDate%22%3A%222025-05-26%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BVilleneuve%2C%20Thomas%2C%20Thibaut%20Jamme%2C%20Robin%20Schwob%2C%20Thierry%20Levade%2C%20and%20Gr%26%23xE9%3Bgoire%20Pr%26%23xE9%3Bvot.%20%26%23x201C%3BAdvanced%20Strategies%20for%20Detecting%20Acid%20Sphingomyelinase%20Deficiency%20Type%20B%20with%20Attenuated%20Phenotypes.%26%23x201D%3B%20%26lt%3Bi%26gt%3BOrphanet%20Journal%20of%20Rare%20Diseases%26lt%3B%5C%2Fi%26gt%3B%2020%2C%20no.%201%20%28May%2026%2C%202025%29%3A%20252.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13023-025-03746-9%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13023-025-03746-9%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Advanced%20strategies%20for%20detecting%20acid%20sphingomyelinase%20deficiency%20type%20B%20with%20attenuated%20phenotypes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Villeneuve%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaut%22%2C%22lastName%22%3A%22Jamme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robin%22%2C%22lastName%22%3A%22Schwob%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gr%5Cu00e9goire%22%2C%22lastName%22%3A%22Pr%5Cu00e9vot%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Acid%20Sphingomyelinase%20Deficiency%20%28ASMD%29%20type%20B%20is%20a%20rare%20lysosomal%20disorder%20caused%20by%20SMPD1%20mutations.%20Due%20to%20its%20low%20prevalence%20and%20clinical%20heterogeneity%2C%20diagnosis%20is%20challenging%2C%20and%20detection%20is%20crucial%20for%20the%20initiation%20of%20enzyme%20replacement%20therapy.%5CnMETHODS%3A%20We%20conducted%20a%20retrospective%20study%20%28RnIPH%202024-85%29%20at%20Toulouse%20University%20Hospital%2C%20analyzing%20359%2C802%20lipid%20profiles%20%282012-2023%29.%20We%20identified%20individuals%20with%20a%20total%20cholesterol%5C%2FHDL%20cholesterol%20ratio%5Cu2009%26gt%3B%5Cu20094.5.%20A%20regex-based%20extraction%20method%20screened%20records%20for%20consanguinity%2C%20hepatomegaly%2C%20splenomegaly%2C%20and%20ground-glass%20opacities%20%28GGOs%29%2C%20while%20we%20also%20analyzed%20thrombocytopenia%20%28%26lt%3B%5Cu2009150%5Cu2009%5Cu00d7%5Cu200910%5Cu2079%5C%2FL%29.%20Patients%20meeting%5Cu2009%5Cu2265%5Cu20094%5C%2F5%20criteria%20underwent%20clinical%20review.%5CnRESULTS%3A%20Among%2063%2C653%20patients%20with%20dyslipidemia%2C%2020.3%25%20had%20thrombocytopenia%2C%204.93%25%20hepatosplenomegaly%2C%202.29%25%20GGOs%2C%20and%200.24%25%20consanguinity.%20In%20total%2C%20179%20patients%20met%5Cu2009%5Cu2265%5Cu20094%5C%2F5%20criteria.%20Nineteen%20%2810.6%25%29%20were%20pediatric.%20Three%20previously%20diagnosed%20ASMD%20type%20B%20patients%20in%20our%20center%20were%20identified.%20Additionally%2C%20among%20other%20conditions%2C%2046%20cases%20%2825.7%25%29%20had%20monogenic%20diseases%2C%20and%20five%20undiagnosed%20patients%20were%20flagged%20for%20ASMD%20screening.%5CnCONCLUSION%3A%20Our%20hybrid%20screening%20effectively%20identified%20ASMD%20type%20B%20cases%20and%20potential%20candidates%20for%20genetic%20testing.%20This%20approach%20combining%20algorithmic%20filtering%20and%20clinical%20expertise%2C%20could%20enhance%20ASMD%20type%20B%20diagnosis.%22%2C%22date%22%3A%222025-05-26%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs13023-025-03746-9%22%2C%22ISSN%22%3A%221750-1172%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222025-05-28T07%3A05%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22GYD9CG56%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Krug%20et%20al.%22%2C%22parsedDate%22%3A%222025-05-20%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BKrug%2C%20Adrien%2C%20Lena%20M.%20Ernst%2C%20Rana%20Mhaidly%2C%20Joana%20Ramis%2C%20Muriel%20F.%20Gusta%2C%20Neus%20G.%20Bastus%2C%20Adriana%20Martinez-Turtos%2C%20et%20al.%20%26%23x201C%3BScavenging%20Reactive%20Oxygen%20Species%20by%20Cerium%20Oxide%20Nanoparticles%20Prevents%20Death%20in%20a%20Peripheral%20T%20Cell%20Lymphoma%20Preclinical%20Mouse%20Model.%26%23x201D%3B%20%26lt%3Bi%26gt%3BACS%20Nano%26lt%3B%5C%2Fi%26gt%3B%2019%2C%20no.%2019%20%28May%2020%2C%202025%29%3A%2018644%26%23x2013%3B60.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1021%5C%2Facsnano.5c02860%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1021%5C%2Facsnano.5c02860%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Scavenging%20Reactive%20Oxygen%20Species%20by%20Cerium%20Oxide%20Nanoparticles%20Prevents%20Death%20in%20a%20Peripheral%20T%20Cell%20Lymphoma%20Preclinical%20Mouse%20Model%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrien%22%2C%22lastName%22%3A%22Krug%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lena%20M.%22%2C%22lastName%22%3A%22Ernst%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rana%22%2C%22lastName%22%3A%22Mhaidly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joana%22%2C%22lastName%22%3A%22Ramis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%20F.%22%2C%22lastName%22%3A%22Gusta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neus%20G.%22%2C%22lastName%22%3A%22Bastus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adriana%22%2C%22lastName%22%3A%22Martinez-Turtos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9a%22%2C%22lastName%22%3A%22Di%20Mascio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gamze%22%2C%22lastName%22%3A%22Tari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Boyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Gaulard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Lemonnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Ehrland%22%2C%22lastName%22%3A%22Ricci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Els%22%2C%22lastName%22%3A%22Verhoeyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victor%22%2C%22lastName%22%3A%22Puntes%22%7D%5D%2C%22abstractNote%22%3A%22Cancer%20cell%20survival%20and%20proliferation%20are%20correlated%20with%20increased%20metabolic%20activity%20and%20consequent%20oxidative%20stress%2C%20driving%20metabolic%20shifts%20that%20interfere%20with%20the%20immune%20response%20to%20malignant%20cells.%20This%20is%20the%20case%20of%20high-energy-demanding%20angioimmunoblastic%20T%20cell%20lymphoma%20%28AITL%29%2C%20a%20highly%20aggressive%20cancer%20with%20poor%20survival%20rates%2C%20where%20malignant%20CD4%2B%20PD-1high%20T%20cells%20show%20increased%20mitochondrial%20activity%20and%20Reactive%20oxygen%20species%20%28ROS%29%20accumulation.%20Here%2C%20we%20report%20that%20administration%20of%20ROS%20scavenging%20cerium%20oxide%20%28CeO2%29%20nanoparticles%20in%20an%20AITL%20preclinical%20mouse%20model%20leads%20to%20their%20preferential%20accumulation%20in%20the%20spleen%2C%20where%20the%20CD4%2B%20PD-1high%20T%20cells%20driving%20malignancy%20were%20significantly%20reduced.%20This%20was%20accompanied%20by%20activation%20of%20previously%20exhausted%20cytotoxic%20CD8%2B%20T%20cells%2C%20restoring%20their%20potent%20antitumor%20function.%20As%20a%20result%2C%20survival%20rates%20dramatically%20increase%20with%20no%20observed%20toxicity%20to%20healthy%20cells%20or%20tissues.%20Overall%2C%20it%20highlights%20the%20correlation%20between%20increased%20energy%20demand%2C%20increased%20mitochondrial%20mass%2C%20increased%20PD-1%20expression%2C%20increased%20ROS%20production%2C%20and%20immune%20suppression%20and%20how%20this%20vicious%20loop%20can%20be%20stopped%20by%20scavenging%20ROS.%22%2C%22date%22%3A%222025-05-20%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1021%5C%2Facsnano.5c02860%22%2C%22ISSN%22%3A%221936-086X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%2C%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222025-11-11T18%3A53%3A04Z%22%7D%7D%2C%7B%22key%22%3A%22A3QW2CTH%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kappler-Gratias%20et%20al.%22%2C%22parsedDate%22%3A%222025-05-17%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BKappler-Gratias%2C%20Sandrine%2C%20Charlotte%20Quentin-Froignant%2C%20Elie%20Marcheteau%2C%20Jos%26%23xE9%3B%20Fernandez%2C%20David%20Boutolleau%2C%20Virginie%20Garcia%2C%20Vincent%20Roy%2C%20Luigi%20A.%20Agrofoglio%2C%20and%20Franck%20Gallardo.%20%26%23x201C%3BLAVR-289%2C%20an%20Acyclo-Nucleoside%20Phosphonate%2C%20Has%20Broad-Spectrum%20Activity%20against%20Herpesviruses.%26%23x201D%3B%20%26lt%3Bi%26gt%3BACS%20Infectious%20Diseases%26lt%3B%5C%2Fi%26gt%3B%2C%20May%2017%2C%202025.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1021%5C%2Facsinfecdis.5c00171%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1021%5C%2Facsinfecdis.5c00171%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22LAVR-289%2C%20an%20Acyclo-Nucleoside%20Phosphonate%2C%20Has%20Broad-Spectrum%20Activity%20against%20Herpesviruses%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Kappler-Gratias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Quentin-Froignant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elie%22%2C%22lastName%22%3A%22Marcheteau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%22%2C%22lastName%22%3A%22Fernandez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Boutolleau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Roy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luigi%20A.%22%2C%22lastName%22%3A%22Agrofoglio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Gallardo%22%7D%5D%2C%22abstractNote%22%3A%22Human%20herpesviruses%20are%20large%20dsDNA%20viruses%20that%20primarily%20cause%20opportunistic%20infections%20in%20healthy%20adults%20but%20can%20trigger%20life-threatening%20infections%20in%20immunocompromised%20patients.%20Previously%2C%20antivirals%20have%20been%20developed%20against%20a%20variety%20of%20herpesviruses%3B%20these%20include%20acyclovir%20for%20herpes%20simplex%20viruses%20%28HSV1%20and%202%29%20and%20ganciclovir%20and%20letermovir%20for%20human%20cytomegalovirus%20%28hCMV%29.%20However%2C%20broad-spectrum%20inhibitors%20of%20herpesvirus%20infections%20are%20still%20lacking.%20Here%20we%20report%20the%20efficacy%20of%20LAVR-289%2C%20a%20new%20acyclic%20nucleoside%20analogue%2C%20on%20a%20broad%20range%20of%20herpesviruses%20of%20human%20and%20animal%20origin.%20LAVR-289%20displays%20nanomolar%20efficacy%20in%20vitro%2C%20is%20active%20on%20viral%20strains%20resistant%20to%20gold-standard%20antivirals%20and%20is%20efficacious%20ex%20vivo%20on%20reconstituted%20human%20skin%20infected%20with%20HSV1.%20In%20addition%2C%20the%20activity%20of%20LAVR-289%20against%20poxviruses%20and%20adenoviruses%20is%20an%20indication%20of%20its%20potential%20for%20the%20management%20of%20opportunistic%20virus%20infections%20in%20immunocompromised%20patients.%22%2C%22date%22%3A%222025-05-17%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1021%5C%2Facsinfecdis.5c00171%22%2C%22ISSN%22%3A%222373-8227%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222025-05-28T07%3A08%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22GHXR7HRH%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mandia%20et%20al.%22%2C%22parsedDate%22%3A%222025-04-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMandia%2C%20Daniele%2C%20Juliette%20Dufour%2C%20Silvia%20Fenu%2C%20Ettore%20Salsano%2C%20Chiara%20Benzoni%2C%20Fran%26%23xE7%3Bois%20Sellal%2C%20Jeremie%20Pariente%2C%20et%20al.%20%26%23x201C%3BNatural%20History%20of%20Adult-Onset%20Metachromatic%20Leukodystrophy.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Neurology%26lt%3B%5C%2Fi%26gt%3B%20272%2C%20no.%204%20%28April%201%2C%202025%29%3A%20303.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00415-025-12997-2%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00415-025-12997-2%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Natural%20history%20of%20adult-onset%20metachromatic%20leukodystrophy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniele%22%2C%22lastName%22%3A%22Mandia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliette%22%2C%22lastName%22%3A%22Dufour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Silvia%22%2C%22lastName%22%3A%22Fenu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ettore%22%2C%22lastName%22%3A%22Salsano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chiara%22%2C%22lastName%22%3A%22Benzoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Sellal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremie%22%2C%22lastName%22%3A%22Pariente%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nilg%5Cu00fcn%22%2C%22lastName%22%3A%22Cengiz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magali%22%2C%22lastName%22%3A%22Pettazzoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Foudil%22%2C%22lastName%22%3A%22Lamari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Caillaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roberta%22%2C%22lastName%22%3A%22La%20Piana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Brassat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Durand-Dubief%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9rard%22%2C%22lastName%22%3A%22Besson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Odent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Devos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lanie%22%2C%22lastName%22%3A%22Barbay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Makrygianni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hojka%20Gregoric%22%2C%22lastName%22%3A%22Kumperscak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roseline%22%2C%22lastName%22%3A%22Froissart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Nadjar%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222025-04-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00415-025-12997-2%22%2C%22ISSN%22%3A%221432-1459%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222025-04-08T09%3A23%3A46Z%22%7D%7D%2C%7B%22key%22%3A%22KAUIDK67%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Virazels%20et%20al.%22%2C%22parsedDate%22%3A%222025-03-18%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BVirazels%2C%20Mathieu%2C%20Am%26%23xE9%3Blie%20Lusque%2C%20St%26%23xE9%3Bphanie%20Brayer%2C%20Matthieu%20Genais%2C%20Carine%20Dufau%2C%20Jean%20Milh%26%23xE8%3Bs%2C%20Thomas%20Filleron%2C%20et%20al.%20%26%23x201C%3BTNF%20Signature%20in%20Advanced%20Melanoma%20Patients%20Treated%20with%20Immune%20Checkpoint%20Inhibitors%3A%20Results%20from%20the%20MELANF%26%23x3B1%3B%20Clinical%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInternational%20Journal%20of%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2C%20March%2018%2C%202025.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fijc.35416%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fijc.35416%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22TNF%20signature%20in%20advanced%20melanoma%20patients%20treated%20with%20immune%20checkpoint%20inhibitors%3A%20Results%20from%20the%20MELANF%5Cu03b1%20clinical%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Virazels%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Lusque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Brayer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthieu%22%2C%22lastName%22%3A%22Genais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Dufau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Milh%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Pag%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Sibaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Mortier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Dereure%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amandine%22%2C%22lastName%22%3A%22Fabre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Andrieu-Abadie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vera%22%2C%22lastName%22%3A%22Pancaldi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Colacios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22S%5Cu00e9gui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Montfort%22%7D%5D%2C%22abstractNote%22%3A%22Resistance%20to%20immune%20checkpoint%20inhibitors%20%28ICI%29%20in%20cancer%20patients%20is%20not%20fully%20understood%2C%20and%20predictive%20biomarkers%20are%20lacking.%20MELANF%5Cu03b1%20%28NCT03348891%29%20is%20an%20open-label%2C%20prospective%2C%20multicenter%20cohort%20of%2060%20patients%20with%20advanced%20melanoma%20receiving%20ICI%20%28bitherapy%3A%20ipilimumab%20%2B%20nivolumab%3B%20monotherapy%3A%20pembrolizumab%20or%20nivolumab%29.%20The%20primary%20objective%20was%20to%20evaluate%20whether%20changes%20in%20plasma%20TNF%20between%20baseline%20%28W0%29%20and%20week%2012%20%28W12%29%20identified%20patients%20with%20non-progressive%20disease%20at%20W12.%20Secondary%20and%20exploratory%20objectives%20were%20to%20assess%20the%20association%20between%20plasma%20TNF%2C%20tumor%20response%2C%20and%20changes%20in%20circulating%20T%20cells.%20Plasma%20TNF%20increased%20along%20therapy%2C%20but%20its%20W12%5C%2FW0%20fold%20change%20was%20not%20associated%20with%20non-progressive%20disease%20at%20W12.%20However%2C%20plasma%20TNF%20levels%20at%20W12%20were%20significantly%20higher%20in%20non-responders%20than%20in%20responders%20across%20therapies%20%28p%5Cu2009%3D%5Cu2009.0129%29.%20The%20remodeling%20of%20circulating%20T%20cell%20subpopulations%20was%20mostly%20triggered%20by%20bitherapy.%20Increased%20proportions%20of%20circulating%20central%20memory%20and%20effector%20memory%20CD8%20T%20cells%20after%20bitherapy%20were%20positively%20and%20negatively%20associated%20with%20response%20to%20treatment%2C%20respectively.%20In%20this%20cohort%2C%20circulating%20T%20cells%20from%20responders%20and%20non-responders%20also%20displayed%20distinct%20molecular%20characteristics.%20Indeed%2C%20responders%20showed%20an%20increased%20proportion%20of%20CD8%20T%20cells%20with%20low%20enrichment%20of%20TNF-related%20pathways%20and%20high%20cytotoxic%20potential%2C%20while%20non-responders%20displayed%20increased%20proportions%20of%20circulating%20CD8%20EM%20T%20cells%20enriched%20for%20TNF-related%20pathways%20and%20directed%20toward%20cytokine%20expression.%20In%20conclusion%2C%20our%20study%20shows%20that%20elevated%20plasma%20TNF%20and%20enriched%20TNF%20pathways%20in%20T%20cells%20are%20associated%20with%20poorer%20clinical%20outcomes%2C%20reinforcing%20the%20notion%20that%20TNF%20may%20dampen%20ICI%20efficacy.%22%2C%22date%22%3A%222025-03-18%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fijc.35416%22%2C%22ISSN%22%3A%221097-0215%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222025-03-24T13%3A21%3A10Z%22%7D%7D%2C%7B%22key%22%3A%22S73QLWR7%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Froissart%20et%20al.%22%2C%22parsedDate%22%3A%222025-03-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFroissart%2C%20Roseline%2C%20Magali%20Pettazzoni%2C%20C%26%23xE9%3Bcile%20Pagan%2C%20Thierry%20Levade%2C%20and%20Marie%20T.%20Vanier.%20%26%23x201C%3BAcid%20Sphingomyelinase%20Deficiency%3A%20Laboratory%20Diagnosis%2C%20Genetic%20and%20Epidemiologic%20Aspects%20of%20a%2050-Year%20French%20Cohort.%26%23x201D%3B%20%26lt%3Bi%26gt%3BMolecular%20Genetics%20and%20Metabolism%26lt%3B%5C%2Fi%26gt%3B%20145%2C%20no.%201%20%28March%2011%2C%202025%29%3A%20109081.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ymgme.2025.109081%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ymgme.2025.109081%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Acid%20sphingomyelinase%20deficiency%3A%20Laboratory%20diagnosis%2C%20genetic%20and%20epidemiologic%20aspects%20of%20a%2050-year%20French%20cohort%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roseline%22%2C%22lastName%22%3A%22Froissart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magali%22%2C%22lastName%22%3A%22Pettazzoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Pagan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20T.%22%2C%22lastName%22%3A%22Vanier%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20Laboratory%20diagnosis%20of%20acid%20sphingomyelinase%20%28ASM%29%20deficiency%20%28ASMD%29%20was%20implemented%20in%20France%20in%20the%20early%201970s.%20The%20aims%20of%20this%20study%20were%20%28i%29%20to%20review%20the%20combined%20use%20of%20successively%20developed%20strategies%20-%20enzyme%20measurement%2C%20genetic%20testing%2C%20and%20biomarkers%20analysis%20-%20and%20%28ii%29%20to%20describe%20the%20mutational%20spectrum%20and%20epidemiological%20characteristics%20of%20a%20large%20patient%20cohort%20followed%20in%20French%20hospitals.%5CnRESULTS%3A%20During%20the%201974-2023%20period%2C%20271%20patients%20with%20ASMD%20%28238%20families%29%20were%20diagnosed.%20The%20chronic%20visceral%20form%20%28historical%20Niemann-Pick%20type%20B%29%20constituted%2068%5Cu00a0%25%20of%20the%20cases%2C%20the%20infantile%20neurovisceral%20%28type%20A%29%20form%2023%5Cu00a0%25%2C%20and%20the%20chronic%20neurovisceral%20%28type%20AB%29%20form%209%5Cu00a0%25.%20Profoundly%20deficient%20ASM%20activities%20were%20constantly%20observed%20in%20the%20neuronopathic%20forms.%20Elevated%20plasma%20concentrations%20of%20LysoSM%20and%20LysoSM-509%5C%2FPPCS%20proved%20useful%20to%20comfort%20interpretation%20of%20ASM%20activities%20near%20cut-off%20found%20in%20leukocytes%20or%20dried%20blood%20spots%20of%20some%20patients%20with%20ASMD%20type%20B.%20Although%20not%20specific%2C%20LysoSM-509%5C%2FPPCS%20appeared%20as%20the%20most%20sensitive%20biomarker.%20The%20spectrum%20of%20SMPD1%20variants%20was%20investigated%20in%20183%20families.%20A%20total%20of%2093%20different%20SMPD1%20variants%20%2826%20novel%20ones%29%20was%20identified%20%2858%5Cu00a0%25%20missense%2C%2019%5Cu00a0%25%20frameshift%2C%20and%2012%5Cu00a0%25%20nonsense%20ones%29.%20The%20proportion%20of%20null%20variants%20was%20much%20larger%20in%20ASMD%20type%20A%20%2863%5Cu00a0%25%29%20than%20in%20type%20B%20%2824%5Cu00a0%25%29.%20In%20type%20AB%2C%20c.1177%5Cu00a0T%5Cu00a0%26gt%3B%5Cu00a0G%20%28p.Trp393Gly%29%20contributed%2032%5Cu00a0%25%20of%20the%20mutant%20alleles%2C%20most%20patients%20having%20Romani%20or%20Northwestern-Balkanic%20roots%2C%20while%20c.880C%5Cu00a0%26gt%3B%5Cu00a0A%20%28p.Gln294Lys%29%20only%20accounted%20for%209%5Cu00a0%25.%20Homoallelic%20variants%20in%20neuronopathic%20patients%20allowed%20genotype%5C%2Fphenotype%20correlations.%20In%20type%20B%2C%20c.1829_1831delGCC%20%28p.Arg610del%29%20represented%2057%5Cu00a0%25%20of%20alleles%2C%20with%20a%20wide%20diversity%20of%20other%20variants.%20Among%20type%20B%20families%2C%20approximately%20one-third%20had%20a%20North%20African%20origin%2C%20and%20this%20variant%20accounted%20for%2091%5Cu00a0%25%20alleles%20in%20this%20subgroup%2C%20compared%20to%2040%5Cu00a0%25%20in%20non-North-African%20families.%20In%20patients%20homozygous%20for%20p.Arg610del%20%28n%5Cu00a0%3D%5Cu00a069%29%2C%20the%20age%20at%20biological%20diagnosis%20was%20significantly%20higher%20%2834.0%5Cu00a0years%3B%20IQR%207.4-45.3%29%20than%20in%20patients%20with%20either%20one%20%28n%5Cu00a0%3D%5Cu00a041%29%20%5B4.3%5Cu00a0years%3B%20IQR%202.77-18.30%5D%20or%20no%20such%20allele%20%28n%5Cu00a0%3D%5Cu00a043%29%20%5B6.3%5Cu00a0years%3B%20IQR%202.2-31.7%5D.%20A%20further%20observation%20was%20the%20proportional%20increase%20in%20the%20number%20of%20type%20B%20patients%20diagnosed%20after%20the%20age%20of%2030%5Cu00a0years%20since%202015.%20This%20nearly%20complete%20national%20cohort%20allowed%20a%20tentative%20evaluation%20of%20%28minimal%29%20incidences%20at%20birth%20as%20follows%3A%20ASMD%20%28all%20clinical%20forms%29%3A%200.70%5C%2F100%2C000%3B%20type%20B%3A%200.48%5C%2F100%2C000%3B%20neuronopathic%20types%20%28A%20and%20AB%29%3A%200.22%5C%2F100%2C000.%5CnCONCLUSIONS%3A%20This%20comprehensive%20cohort%20%28i%29%20summarizes%20the%20real-life%20experience%20of%20laboratory%20diagnosis%20of%20ASMD%20in%20two%20expert%20centres%2C%20%28ii%29%20confirms%20the%20high%20frequency%20of%20the%20p.Arg610del%20allele%20in%20France%20and%20discloses%20some%20characteristics%20of%20patients%20homozygous%20for%20this%20variant%3B%20%28iii%29%20provides%20for%20the%20first%20time%20data%20on%20the%20distribution%2C%20mutational%20spectrum%20and%20tentative%20incidence%20at%20birth%20of%20the%20three%20clinical%20phenotypes%20of%20ASMD%20in%20France.%22%2C%22date%22%3A%222025-03-11%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ymgme.2025.109081%22%2C%22ISSN%22%3A%221096-7206%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222025-03-20T12%3A50%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22K82NWMCQ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dubot%20et%20al.%22%2C%22parsedDate%22%3A%222025-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDubot%2C%20Patricia%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Brique%20Sabourdy%2C%20and%20Thierry%20Levade.%20%26%23x201C%3BHuman%20Genetic%20Defects%20of%20Sphingolipid%20Synthesis.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Inherited%20Metabolic%20Disease%26lt%3B%5C%2Fi%26gt%3B%2048%2C%20no.%201%20%28January%202025%29%3A%20e12745.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjimd.12745%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fjimd.12745%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Human%20genetic%20defects%20of%20sphingolipid%20synthesis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Dubot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9rique%22%2C%22lastName%22%3A%22Sabourdy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%5D%2C%22abstractNote%22%3A%22Sphingolipids%20are%20ubiquitous%20lipids%2C%20present%20in%20the%20membranes%20of%20all%20cell%20types%2C%20the%20stratum%20corneum%20and%20the%20circulating%20lipoproteins.%20Autosomal%20recessive%20as%20well%20as%20dominant%20diseases%20due%20to%20disturbed%20sphingolipid%20biosynthesis%20have%20been%20identified%2C%20including%20defects%20in%20the%20synthesis%20of%20ceramides%2C%20sphingomyelins%20and%20glycosphingolipids.%20In%20many%20instances%2C%20these%20gene%20variants%20result%20in%20the%20loss%20of%20catalytic%20function%20of%20the%20mutated%20enzymes.%20Additional%20gene%20defects%20implicate%20the%20subcellular%20localization%20of%20the%20sphingolipid-synthesizing%20enzyme%2C%20the%20regulation%20of%20its%20activity%2C%20or%20even%20the%20function%20of%20a%20sphingolipid-transporter%20protein.%20The%20resulting%20metabolic%20alterations%20lead%20to%20two%20major%2C%20non-exclusive%20types%20of%20clinical%20manifestations%3A%20a%20neurological%20disease%2C%20more%20or%20less%20rapidly%20progressive%2C%20associated%20or%20not%20with%20intellectual%20disability%2C%20and%20an%20ichthyotic-type%20skin%20disorder.%20These%20phenotypes%20highlight%20the%20critical%20importance%20of%20sphingolipids%20in%20brain%20and%20skin%20development%20and%20homeostasis.%20The%20present%20article%20reviews%20the%20clinical%20symptoms%2C%20genetic%20and%20biochemical%20alterations%2C%20pathophysiological%20mechanisms%20and%20therapeutic%20options%20of%20this%20relatively%20novel%20group%20of%20metabolic%20diseases.%22%2C%22date%22%3A%222025-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fjimd.12745%22%2C%22ISSN%22%3A%221573-2665%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222025-03-10T14%3A35%3A54Z%22%7D%7D%5D%7D
Villeneuve, Thomas, Thibaut Jamme, Robin Schwob, Thierry Levade, and Grégoire Prévot. “Correction: Advanced Strategies for Detecting Acid Sphingomyelinase Deficiency Type B with Attenuated Phenotypes.” Orphanet Journal of Rare Diseases 20, no. 1 (November 25, 2025): 604. https://doi.org/10.1186/s13023-025-03996-7.
Xu, TianMeng, Rachel Heon-Roberts, Travis Moore, Patricia Dubot, Xuefang Pan, Tianlin Guo, Christopher W. Cairo, et al. “Neuraminidase 1 Secondary Deficiency Contributes to CNS Pathology in Neurological Mucopolysaccharidoses via Brain Protein Hypersialylation.” The Journal of Clinical Investigation 135, no. 16 (August 15, 2025): e177430. https://doi.org/10.1172/JCI177430.
Villeneuve, Thomas, Thibaut Jamme, Robin Schwob, Thierry Levade, and Grégoire Prévot. “Advanced Strategies for Detecting Acid Sphingomyelinase Deficiency Type B with Attenuated Phenotypes.” Orphanet Journal of Rare Diseases 20, no. 1 (May 26, 2025): 252. https://doi.org/10.1186/s13023-025-03746-9.
Krug, Adrien, Lena M. Ernst, Rana Mhaidly, Joana Ramis, Muriel F. Gusta, Neus G. Bastus, Adriana Martinez-Turtos, et al. “Scavenging Reactive Oxygen Species by Cerium Oxide Nanoparticles Prevents Death in a Peripheral T Cell Lymphoma Preclinical Mouse Model.” ACS Nano 19, no. 19 (May 20, 2025): 18644–60. https://doi.org/10.1021/acsnano.5c02860.
Kappler-Gratias, Sandrine, Charlotte Quentin-Froignant, Elie Marcheteau, José Fernandez, David Boutolleau, Virginie Garcia, Vincent Roy, Luigi A. Agrofoglio, and Franck Gallardo. “LAVR-289, an Acyclo-Nucleoside Phosphonate, Has Broad-Spectrum Activity against Herpesviruses.” ACS Infectious Diseases, May 17, 2025. https://doi.org/10.1021/acsinfecdis.5c00171.
Mandia, Daniele, Juliette Dufour, Silvia Fenu, Ettore Salsano, Chiara Benzoni, François Sellal, Jeremie Pariente, et al. “Natural History of Adult-Onset Metachromatic Leukodystrophy.” Journal of Neurology 272, no. 4 (April 1, 2025): 303. https://doi.org/10.1007/s00415-025-12997-2.
Virazels, Mathieu, Amélie Lusque, Stéphanie Brayer, Matthieu Genais, Carine Dufau, Jean Milhès, Thomas Filleron, et al. “TNF Signature in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors: Results from the MELANFα Clinical Study.” International Journal of Cancer, March 18, 2025. https://doi.org/10.1002/ijc.35416.
Froissart, Roseline, Magali Pettazzoni, Cécile Pagan, Thierry Levade, and Marie T. Vanier. “Acid Sphingomyelinase Deficiency: Laboratory Diagnosis, Genetic and Epidemiologic Aspects of a 50-Year French Cohort.” Molecular Genetics and Metabolism 145, no. 1 (March 11, 2025): 109081. https://doi.org/10.1016/j.ymgme.2025.109081.
Dubot, Patricia, Frédérique Sabourdy, and Thierry Levade. “Human Genetic Defects of Sphingolipid Synthesis.” Journal of Inherited Metabolic Disease 48, no. 1 (January 2025): e12745. https://doi.org/10.1002/jimd.12745.
PUBLICATIONS 2024
7813506
KC3WFBJR
2024
1
chicago-fullnote-bibliography
50
date
desc
42676
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22D67W6WKE%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Combarel%20et%20al.%22%2C%22parsedDate%22%3A%222024-05-16%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCombarel%2C%20David%2C%20L%26%23xE9%3Ba%20Dousset%2C%20St%26%23xE9%3Bphane%20Bouchet%2C%20Florent%20Ferrer%2C%20Pauline%20Tetu%2C%20C%26%23xE9%3Bleste%20Lebbe%2C%20Joseph%20Ciccolini%2C%20Nicolas%20Meyer%2C%20and%20Angelo%20Paci.%20%26%23x201C%3BTyrosine%20Kinase%20Inhibitors%20in%20Cancers%3A%20Treatment%20Optimization%20-%20Part%20I.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCritical%20Reviews%20in%20Oncology%5C%2FHematology%26lt%3B%5C%2Fi%26gt%3B%2C%20May%2016%2C%202024%2C%20104384.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.critrevonc.2024.104384%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.critrevonc.2024.104384%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Tyrosine%20Kinase%20Inhibitors%20in%20Cancers%3A%20treatment%20optimization%20-%20Part%20I%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Combarel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9a%22%2C%22lastName%22%3A%22Dousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Bouchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Ferrer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Tetu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9leste%22%2C%22lastName%22%3A%22Lebbe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Ciccolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angelo%22%2C%22lastName%22%3A%22Paci%22%7D%5D%2C%22abstractNote%22%3A%22A%20multitude%20of%20TKI%20has%20been%20developed%20and%20approved%20targeting%20various%20oncogenetic%20alterations.%20While%20these%20have%20provided%20improvements%20in%20efficacy%20compared%20with%20conventional%20chemotherapies%2C%20resistance%20to%20targeted%20therapies%20occurs.%20Mutations%20in%20the%20kinase%20domain%20result%20in%20the%20inability%20of%20TKI%20to%20inactivate%20the%20protein%20kinase.%20Also%2C%20gene%20amplification%2C%20increased%20protein%20expression%20and%20downstream%20activation%20or%20bypassing%20of%20signalling%20pathways%20are%20commonly%20reported%20mechanisms%20of%20resistance.%20Improved%20understanding%20of%20mechanisms%20involved%20in%20TKI%20resistance%20has%20resulted%20in%20the%20development%20of%20new%20generations%20of%20targeted%20agents.%20In%20a%20race%20against%20time%2C%20the%20search%20for%20new%2C%20more%20potent%20and%20efficient%20drugs%2C%20and%5C%2For%20combinations%20of%20drugs%2C%20remains%20necessary%20as%20new%20resistance%20mechanisms%20to%20the%20latest%20generation%20of%20TKI%20emerge.%20This%20review%20examines%20the%20various%20generations%20of%20TKI%20approved%20to%20date%20and%20their%20common%20mechanisms%20of%20resistance%2C%20focusing%20on%20TKI%20targeting%20BCR-ABL%2C%20epidermal%20growth%20factor%20receptor%2C%20anaplastic%20lymphoma%20kinase%20and%20BRAF%5C%2FMEK%20tyrosine%20kinases.%22%2C%22date%22%3A%222024-05-16%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.critrevonc.2024.104384%22%2C%22ISSN%22%3A%221879-0461%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222024-05-20T15%3A42%3A08Z%22%7D%7D%2C%7B%22key%22%3A%2227J44QYJ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Borie-Guichot%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-16%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBorie-Guichot%2C%20Marc%2C%20My%20Lan%20Tran%2C%20Virginie%20Garcia%2C%20Abdelouahd%20Oukhrib%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Rodriguez%2C%20C%26%23xE9%3Bdric-Olivier%20Turrin%2C%20Thierry%20Levade%2C%20Yves%20G%26%23xE9%3Bnisson%2C%20St%26%23xE9%3Bphanie%20Ballereau%2C%20and%20C%26%23xE9%3Bcile%20Dehoux.%20%26%23x201C%3BMultivalent%20Pyrrolidines%20Acting%20as%20Pharmacological%20Chaperones%20against%20Gaucher%20Disease.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBioorganic%20Chemistry%26lt%3B%5C%2Fi%26gt%3B%20146%20%28March%2016%2C%202024%29%3A%20107295.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bioorg.2024.107295%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bioorg.2024.107295%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Multivalent%20pyrrolidines%20acting%20as%20pharmacological%20chaperones%20against%20Gaucher%20disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Borie-Guichot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22My%22%2C%22lastName%22%3A%22Lan%20Tran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdelouahd%22%2C%22lastName%22%3A%22Oukhrib%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Rodriguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9dric-Olivier%22%2C%22lastName%22%3A%22Turrin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22G%5Cu00e9nisson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Ballereau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Dehoux%22%7D%5D%2C%22abstractNote%22%3A%22A%20concise%20asymmetric%20synthesis%20of%20clickable%20enantiomeric%20pyrrolidines%20was%20achieved%20using%20Crabb%5Cu00e9-Ma%20allenation.%20The%20synthesized%20iminosugars%20were%20grafted%20by%20copper-free%20strain-promoted%20alkyne-azide%20cycloaddition%20onto%20phosphorus%20dendrimers.%20The%20hexavalent%20and%20dodecavalent%20pyrrolidines%20were%20evaluated%20as%20%5Cu03b2-glucocerebrosidase%20inhibitors.%20The%20level%20of%20inhibition%20suggests%20that%20monofluorocyclooctatriazole%20group%20may%20contribute%20to%20the%20affinity%20for%20the%20protein%20leading%20to%20potent%20multivalent%20inhibitors.%20Docking%20studies%20were%20carried%20out%20to%20rationalize%20these%20results.%20Then%2C%20the%20iminosugars%20clusters%20were%20evaluated%20as%20pharmacological%20chaperones%20in%20Gaucher%20patients%26%23039%3B%20fibroblasts.%20An%20increase%20in%20%5Cu03b2-glucocerebrosidase%20activity%20was%20observed%20with%20hexavalent%20and%20dodecavalent%20pyrrolidines%20at%20concentrations%20as%20low%20as%201%5Cu00a0%5Cu00b5M%20and%200.1%5Cu00a0%5Cu00b5M%2C%20respectively.%20These%20iminosugar%20clusters%20constitute%20the%20first%20example%20of%20multivalent%20pyrrolidines%20acting%20as%20pharmacological%20chaperones%20against%20Gaucher%20disease.%22%2C%22date%22%3A%222024-03-16%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.bioorg.2024.107295%22%2C%22ISSN%22%3A%221090-2120%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222024-04-16T10%3A22%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22D6EQU6U8%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Casasampere%20et%20al.%22%2C%22parsedDate%22%3A%222024-02-16%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCasasampere%2C%20Mireia%2C%20Johnson%20Ung%2C%20Alejandro%20I%26%23xF1%3B%26%23xE1%3B%26%23xF1%3Bez%2C%20Carine%20Duffau%2C%20Kazuhito%20Tsuboi%2C%20Josefina%20Casas%2C%20Su-Fern%20Tan%2C%20et%20al.%20%26%23x201C%3BA%20Fluorogenic%20Substrate%20for%20the%20Detection%20of%20Lipid%20Amidases%20in%20Intact%20Cells.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Lipid%20Research%26lt%3B%5C%2Fi%26gt%3B%2C%20February%2016%2C%202024%2C%20100520.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jlr.2024.100520%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jlr.2024.100520%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20fluorogenic%20substrate%20for%20the%20detection%20of%20lipid%20amidases%20in%20intact%20cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mireia%22%2C%22lastName%22%3A%22Casasampere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johnson%22%2C%22lastName%22%3A%22Ung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandro%22%2C%22lastName%22%3A%22I%5Cu00f1%5Cu00e1%5Cu00f1ez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Duffau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kazuhito%22%2C%22lastName%22%3A%22Tsuboi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josefina%22%2C%22lastName%22%3A%22Casas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Su-Fern%22%2C%22lastName%22%3A%22Tan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20J.%22%2C%22lastName%22%3A%22Feith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Andrieu-Abadie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Segui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20P.%22%2C%22lastName%22%3A%22Loughran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20Luis%22%2C%22lastName%22%3A%22Abad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gemma%22%2C%22lastName%22%3A%22Fabrias%22%7D%5D%2C%22abstractNote%22%3A%22Lipid%20amidases%20of%20therapeutic%20relevance%20include%20acid%20ceramidase%20%28AC%29%2C%20N-acylethanolamine-hydrolyzing%20acid%20amidase%20%28NAAA%29%20and%20fatty%20acid%20amide%20hydrolase%20%28FAAH%29.%20Although%20fluorogenic%20substrates%20have%20been%20developed%20for%20the%20three%20enzymes%20and%20high%20throughput%20methods%20for%20screening%20have%20been%20reported%2C%20a%20platform%20for%20the%20specific%20detection%20of%20these%20enzyme%20activities%20in%20intact%20cells%20is%20lacking.%20In%20this%20article%20we%20report%20on%20the%20coumarinic%201-deoxydihydroceramide%20RBM1-151%2C%20a%201-deoxy%20derivative%20and%20vinilog%20of%20RBM14-C12%2C%20as%20a%20novel%20substrate%20of%20amidases.%20This%20compound%20is%20hydrolyzed%20by%20AC%20%28appKm%20%3D%207.0%20%5Cu03bcM%3B%20appVmax%20%3D%2099.3%20nM%5C%2Fmin%29%2C%20NAAA%20%28appKm%20%3D%200.73%20%5Cu03bcM%3B%20appVmax%20%3D%200.24%20nM%5C%2Fmin%29%2C%20and%20FAAH%20%28appKm%20%3D%203.6%20%5Cu03bcM%3B%20appVmax%20%3D%207.6%20nM%5C%2Fmin%29%2C%20but%20not%20by%20other%20ceramidases.%20We%20provide%20proof%20of%20concept%20that%20the%20use%20of%20RBM1-151%20in%20combination%20with%20reported%20irreversible%20inhibitors%20of%20AC%20and%20FAAH%20allows%20the%20determination%20in%20parallel%20of%20the%20three%20amidase%20activities%20in%20single%20experiments%20in%20intact%20cells.%22%2C%22date%22%3A%222024-02-16%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jlr.2024.100520%22%2C%22ISSN%22%3A%221539-7262%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222024-04-02T13%3A58%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22I3RBDBK5%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Krug%20et%20al.%22%2C%22parsedDate%22%3A%222024-02-06%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BKrug%2C%20Adrien%2C%20Marie%20Tosolini%2C%20Blandine%20Madji%20Hounoum%2C%20Jean-Jacques%20Fourni%26%23xE9%3B%2C%20Roger%20Geiger%2C%20Matteo%20Pecoraro%2C%20Patrick%20Emond%2C%20et%20al.%20%26%23x201C%3BInhibition%20of%20Choline%20Metabolism%20in%20an%20Angioimmunoblastic%20T-Cell%20Lymphoma%20Preclinical%20Model%20Reveals%20a%20New%20Metabolic%20Vulnerability%20as%20Possible%20Target%20for%20Treatment.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Experimental%20%26amp%3B%20Clinical%20Cancer%20Research%3A%20CR%26lt%3B%5C%2Fi%26gt%3B%2043%2C%20no.%201%20%28February%206%2C%202024%29%3A%2043.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13046-024-02952-w%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13046-024-02952-w%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Inhibition%20of%20choline%20metabolism%20in%20an%20angioimmunoblastic%20T-cell%20lymphoma%20preclinical%20model%20reveals%20a%20new%20metabolic%20vulnerability%20as%20possible%20target%20for%20treatment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrien%22%2C%22lastName%22%3A%22Krug%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Blandine%22%2C%22lastName%22%3A%22Madji%20Hounoum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Jacques%22%2C%22lastName%22%3A%22Fourni%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roger%22%2C%22lastName%22%3A%22Geiger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matteo%22%2C%22lastName%22%3A%22Pecoraro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Emond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Gaulard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Lemonnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Ehrland%22%2C%22lastName%22%3A%22Ricci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Els%22%2C%22lastName%22%3A%22Verhoeyen%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Angioimmunoblastic%20T-cell%20lymphoma%20%28AITL%29%20is%20a%20malignancy%20with%20very%20poor%20survival%20outcome%2C%20in%20urgent%20need%20of%20more%20specific%20therapeutic%20strategies.%20The%20drivers%20of%20malignancy%20in%20this%20disease%20are%20CD4%2B%20follicular%20helper%20T%20cells%20%28Tfh%29.%20The%20metabolism%20of%20these%20malignant%20Tfh%20cells%20was%20not%20yet%20elucidated.%20Therefore%2C%20we%20decided%20to%20identify%20their%20metabolic%20requirements%20with%20the%20objective%20to%20propose%20a%20novel%20therapeutic%20option.%5CnMETHODS%3A%20To%20reveal%20the%20prominent%20metabolic%20pathways%20used%20by%20the%20AITL%20lymphoma%20cells%2C%20we%20relied%20on%20metabolomic%20and%20proteomic%20analysis%20of%20murine%20AITL%20%28mAITL%29%20T%20cells%20isolated%20from%20our%20established%20mAITL%20model.%20We%20confirmed%20these%20results%20using%20AITL%20patient%20and%20healthy%20T%20cell%20expression%20data.%5CnRESULTS%3A%20Strikingly%2C%20the%20mAITL%20Tfh%20cells%20were%20highly%20dependent%20on%20the%20second%20branch%20of%20the%20Kennedy%20pathway%2C%20the%20choline%20lipid%20pathway%2C%20responsible%20for%20the%20production%20of%20the%20major%20membrane%20constituent%20phosphatidylcholine.%20Moreover%2C%20gene%20expression%20data%20from%20Tfh%20cells%20isolated%20from%20AITL%20patient%20tumors%2C%20confirmed%20the%20upregulation%20of%20the%20choline%20lipid%20pathway.%20Several%20enzymes%20involved%20in%20this%20pathway%20such%20as%20choline%20kinase%2C%20catalyzing%20the%20first%20step%20in%20the%20phosphatidylcholine%20pathway%2C%20are%20upregulated%20in%20multiple%20tumors%20other%20than%20AITL.%20Here%20we%20showed%20that%20treatment%20of%20our%20mAITL%20preclinical%20mouse%20model%20with%20a%20fatty%20acid%20oxydation%20inhibitor%2C%20significantly%20increased%20their%20survival%20and%20even%20reverted%20the%20exhausted%20CD8%20T%20cells%20in%20the%20tumor%20into%20potent%20cytotoxic%20anti-tumor%20cells.%20Specific%20inhibition%20of%20Chok%5Cu03b1%20confirmed%20the%20importance%20of%20the%20phosphatidylcholine%20production%20pathway%20in%20neoplastic%20CD4%5Cu2009%2B%5Cu2009T%20cells%2C%20nearly%20eradicating%20mAITL%20Tfh%20cells%20from%20the%20tumors.%20Finally%2C%20the%20same%20inhibitor%20induced%20in%20human%20AITL%20lymphoma%20biopsies%20cell%20death%20of%20the%20majority%20of%20the%20hAITL%20PD-1high%20neoplastic%20cells.%5CnCONCLUSION%3A%20Our%20results%20suggest%20that%20interfering%20with%20choline%20metabolism%20in%20AITL%20reveals%20a%20specific%20metabolic%20vulnerability%20and%20might%20represent%20a%20new%20therapeutic%20strategy%20for%20these%20patients.%22%2C%22date%22%3A%222024-02-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs13046-024-02952-w%22%2C%22ISSN%22%3A%221756-9966%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%2C%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222024-02-13T10%3A16%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22YWBJAWXZ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rives%20et%20al.%22%2C%22parsedDate%22%3A%222024-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BRives%2C%20Cl%26%23xE9%3Bmence%2C%20C%26%23xE9%3Bline%20Marie%20Pauline%20Martin%2C%20Lauris%20Evariste%2C%20Arnaud%20Polizzi%2C%20Marine%20Huillet%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Lasserre%2C%20Val%26%23xE9%3Brie%20Alquier-Bacquie%2C%20et%20al.%20%26%23x201C%3BDietary%20Amino%20Acid%20Source%20Elicits%20Sex-Specific%20Metabolic%20Response%20to%20Diet-Induced%20NAFLD%20in%20Mice.%26%23x201D%3B%20%26lt%3Bi%26gt%3BMolecular%20Nutrition%20%26amp%3B%20Food%20Research%26lt%3B%5C%2Fi%26gt%3B%2068%2C%20no.%201%20%28January%202024%29%3A%20e2300491.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fmnfr.202300491%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fmnfr.202300491%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Dietary%20Amino%20Acid%20Source%20Elicits%20Sex-Specific%20Metabolic%20Response%20to%20Diet-Induced%20NAFLD%20in%20Mice%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Rives%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%20Marie%20Pauline%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauris%22%2C%22lastName%22%3A%22Evariste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Polizzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Huillet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Lasserre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Alquier-Bacquie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Prunelle%22%2C%22lastName%22%3A%22Perrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jelskey%22%2C%22lastName%22%3A%22Gomez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yannick%22%2C%22lastName%22%3A%22Lippi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Naylies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9rique%22%2C%22lastName%22%3A%22Sabourdy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Remignon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Fafournoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Chassaing%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Loiseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Guillou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Ellero-Simatos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Gamet-Payrastre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Fougerat%22%7D%5D%2C%22abstractNote%22%3A%22SCOPE%3A%20Non-alcoholic%20fatty%20liver%20disease%20%28NAFLD%29%20is%20a%20sexually%20dimorphic%20disease%20influenced%20by%20dietary%20factors.%20Here%2C%20the%20metabolic%20and%20hepatic%20effects%20of%20dietary%20amino%20acid%20%28AA%29%20source%20is%20assessed%20in%20Western%20diet%20%28WD%29-induced%20NAFLD%20in%20male%20and%20female%20mice.%5CnMETHODS%20AND%20RESULTS%3A%20The%20AA%20source%20is%20either%20casein%20or%20a%20free%20AA%20mixture%20mimicking%20the%20composition%20of%20casein.%20As%20expected%2C%20males%20fed%20a%20casein-based%20WD%20display%20glucose%20intolerance%2C%20fasting%20hyperglycemia%2C%20and%20insulin-resistance%20and%20develop%20NAFLD%20associated%20with%20changes%20in%20hepatic%20gene%20expression%20and%20microbiota%20dysbiosis.%20In%20contrast%2C%20males%20fed%20the%20AA-based%20WD%20show%20no%20steatosis%2C%20a%20similar%20gene%20expression%20profile%20as%20males%20fed%20a%20control%20diet%2C%20and%20a%20distinct%20microbiota%20composition%20compared%20to%20males%20fed%20a%20casein-based%20WD.%20Females%20are%20protected%20against%20WD-induced%20liver%20damage%2C%20hepatic%20gene%20expression%2C%20and%20gut%20microbiota%20changes%20regardless%20of%20the%20AA%20source.%5CnCONCLUSIONS%3A%20Free%20dietary%20AA%20intake%20prevents%20the%20unhealthy%20metabolic%20outcomes%20of%20a%20WD%20preferentially%20in%20male%20mice.%22%2C%22date%22%3A%222024-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fmnfr.202300491%22%2C%22ISSN%22%3A%221613-4133%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222024-01-08T10%3A20%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22E5H7V5Z3%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Matta%20et%20al.%22%2C%22parsedDate%22%3A%222024%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMatta%2C%20Anthony%2C%20Fabienne%20Ory%20Magne%2C%20Thierry%20Levade%2C%20Fabrice%20Bonneville%2C%20and%20Jean%20Ferri%26%23xE8%3Bres.%20%26%23x201C%3BCerebrotendinous%20Xanthomatosis%3A%20A%20Literature%20Review%20and%20Case%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BFrontiers%20in%20Cardiovascular%20Medicine%26lt%3B%5C%2Fi%26gt%3B%2011%20%282024%29%3A%201496442.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffcvm.2024.1496442%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffcvm.2024.1496442%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cerebrotendinous%20xanthomatosis%3A%20a%20literature%20review%20and%20case%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Matta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Ory%20Magne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Bonneville%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Ferri%5Cu00e8res%22%7D%5D%2C%22abstractNote%22%3A%22Cerebrotendinous%20xanthomatosis%20%28CTX%29%20is%20a%20rare%20but%20treatable%20inherited%20neurometabolic%20disorder%20that%20can%20lead%20to%20severe%20sequelae%20if%20left%20untreated.%20Chenodeoxycholic%20acid%20is%20a%20safe%20and%20effective%20treatment%20for%20CTX.%20Early%20diagnosis%20is%20essential%20to%20improve%20patient%20outcomes.%20Neurological%20disturbances%2C%20cataracts%2C%20and%20intractable%20diarrhea%20are%20key%20features%20to%20raise%20diagnostic%20suspicion%20and%20differentiate%20CTX%20from%20other%20metabolic%20disorders%20in%20patients%20with%20dyslipidemia%20and%20xanthomas.%20The%20diagnosis%20of%20CTX%20depends%20on%20high%20cholestanol%20plasma%20levels%2C%20undetectable%20plasma%20bile%20acids%2C%20neuroradiological%20findings%2C%20and%20CYP27A1%20gene%20analysis.%20This%20review%20provides%20a%20stepwise%20approach%20to%20diagnosing%20patients%20with%20CTX%2C%20aims%20to%20improve%20physician%20awareness%20of%20CTX%2C%20and%20highlights%20the%20effectiveness%20of%20chenodeoxycholic%20acid%20as%20the%20standard%20of%20care.%20In%20addition%2C%20we%20report%20a%20unique%20case%20of%20CTX%20with%20major%20premature%20cardiovascular%20events%2C%20initially%20misdiagnosed%20as%20heterozygous%20familial%20hypercholesterolemia.%20This%20review%20also%20provides%20evidence%20to%20establish%20the%20c.470T%26gt%3BC%20%28p.%20Leu157Pro%29%20variant%20of%20the%20CYP27A1%20gene%20as%20a%20likely%20pathologic%20variant.%22%2C%22date%22%3A%222024%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3389%5C%2Ffcvm.2024.1496442%22%2C%22ISSN%22%3A%222297-055X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222025-01-03T18%3A17%3A08Z%22%7D%7D%2C%7B%22key%22%3A%22UQW54YNG%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dufau%20et%20al.%22%2C%22parsedDate%22%3A%222024%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDufau%2C%20Carine%2C%20Matthieu%20Genais%2C%20Elodie%20Mucher%2C%20Benjamin%20Jung%2C%20Virginie%20Garcia%2C%20Anne%20Montfort%2C%20Marie%20Tosolini%2C%20et%20al.%20%26%23x201C%3BCeramide%20Metabolism%20Alterations%20Contribute%20to%20Tumor%20Necrosis%20Factor-Induced%20Melanoma%20Dedifferentiation%20and%20Predict%20Resistance%20to%20Immune%20Checkpoint%20Inhibitors%20in%20Advanced%20Melanoma%20Patients.%26%23x201D%3B%20%26lt%3Bi%26gt%3BFrontiers%20in%20Immunology%26lt%3B%5C%2Fi%26gt%3B%2015%20%282024%29%3A%201421432.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2024.1421432%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2024.1421432%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Ceramide%20metabolism%20alterations%20contribute%20to%20Tumor%20Necrosis%20Factor-induced%20melanoma%20dedifferentiation%20and%20predict%20resistance%20to%20immune%20checkpoint%20inhibitors%20in%20advanced%20melanoma%20patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Dufau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthieu%22%2C%22lastName%22%3A%22Genais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Mucher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Jung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Montfort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20J.%22%2C%22lastName%22%3A%22Clarke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%20A.%22%2C%22lastName%22%3A%22Medin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vera%22%2C%22lastName%22%3A%22Pancaldi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Andrieu-Abadie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22S%5Cu00e9gui%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Advanced%20cutaneous%20melanoma%20is%20a%20skin%20cancer%20characterized%20by%20a%20poor%20prognosis%20and%20high%20metastatic%20potential.%20During%20metastatic%20spread%2C%20melanoma%20cells%20often%20undergo%20dedifferentiation%20toward%20an%20invasive%20phenotype%2C%20resulting%20in%20reduced%20expression%20of%20microphthalmia-associated%20transcription%20factor%20%28MITF%29-dependent%20melanoma%20antigens%20and%20facilitating%20immune%20escape.%20Tumor%20Necrosis%20Factor%20%28TNF%29%20is%20known%20to%20be%20a%20key%20factor%20in%20melanoma%20dedifferentiation.%20Interestingly%2C%20accumulating%20evidence%20suggests%20that%20TNF%20may%20play%20a%20role%20in%20melanoma%20progression%20and%20resistance%20to%20immunotherapies.%20Additionally%2C%20TNF%20has%20been%20identified%20as%20a%20potent%20regulator%20of%20sphingolipid%20metabolism%2C%20which%20could%20contribute%20to%20melanoma%20aggressiveness%20and%20the%20process%20of%20melanoma%20dedifferentiation.%5CnMETHODS%3A%20We%20conducted%20RNA%20sequencing%20and%20mass%20spectrometry%20analyses%20to%20investigate%20TNF-induced%20dedifferentiation%20in%20two%20melanoma%20cell%20lines.%20In%20vitro%20experiments%20were%20performed%20to%20manipulate%20sphingolipid%20metabolism%20using%20genetic%20or%20pharmacologic%20alterations%20in%20combination%20with%20TNF%20treatment%2C%20aiming%20to%20elucidate%20the%20potential%20involvement%20of%20this%20metabolism%20in%20TNF-induced%20dedifferentiation.%20Lastly%2C%20to%20evaluate%20the%20clinical%20significance%20of%20our%20findings%2C%20we%20performed%20unsupervised%20analysis%20of%20plasma%20sphingolipid%20levels%20in%2048%20patients%20receiving%20treatment%20with%20immune%20checkpoint%20inhibitors%2C%20either%20alone%20or%20in%20combination%20with%20anti-TNF%20therapy.%5CnRESULTS%3A%20Herein%2C%20we%20demonstrate%20that%20TNF-induced%20melanoma%20cell%20dedifferentiation%20is%20associated%20with%20a%20global%20modulation%20of%20sphingolipid%20metabolism.%20Specifically%2C%20TNF%20decreases%20the%20expression%20and%20activity%20of%20acid%20ceramidase%20%28AC%29%2C%20encoded%20by%20the%20ASAH1%20gene%2C%20while%20increasing%20the%20expression%20of%20glucosylceramide%20synthase%20%28GCS%29%2C%20encoded%20by%20the%20UGCG%20gene.%20Remarkably%2C%20knockdown%20of%20AC%20alone%20via%20RNA%20interference%20is%20enough%20to%20induce%20melanoma%20cell%20dedifferentiation.%20Furthermore%2C%20treatment%20with%20Eliglustat%2C%20a%20GCS%20inhibitor%2C%20inhibits%20TNF-induced%20melanoma%20cell%20dedifferentiation.%20Lastly%2C%20analysis%20of%20plasma%20samples%20from%20patients%20treated%20with%20immune%20checkpoint%20inhibitors%2C%20with%20or%20without%20anti-TNF%20therapy%2C%20revealed%20significant%20predictive%20sphingolipids.%20Notably%2C%20the%20top%208%20predictive%20sphingolipids%2C%20including%20glycosphingolipids%2C%20were%20associated%20with%20a%20poor%20response%20to%20immunotherapy.%5CnDISCUSSION%3A%20Our%20study%20highlights%20that%20ceramide%20metabolism%20alterations%20are%20causally%20involved%20in%20TNF-induced%20melanoma%20cell%20dedifferentiation%20and%20suggests%20that%20the%20evolution%20of%20specific%20ceramide%20metabolites%20in%20plasma%20may%20be%20considered%20as%20predictive%20biomarkers%20of%20resistance%20to%20immunotherapy.%22%2C%22date%22%3A%222024%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3389%5C%2Ffimmu.2024.1421432%22%2C%22ISSN%22%3A%221664-3224%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222024-08-30T08%3A54%3A52Z%22%7D%7D%5D%7D
Combarel, David, Léa Dousset, Stéphane Bouchet, Florent Ferrer, Pauline Tetu, Céleste Lebbe, Joseph Ciccolini, Nicolas Meyer, and Angelo Paci. “Tyrosine Kinase Inhibitors in Cancers: Treatment Optimization - Part I.” Critical Reviews in Oncology/Hematology, May 16, 2024, 104384. https://doi.org/10.1016/j.critrevonc.2024.104384.
Borie-Guichot, Marc, My Lan Tran, Virginie Garcia, Abdelouahd Oukhrib, Frédéric Rodriguez, Cédric-Olivier Turrin, Thierry Levade, Yves Génisson, Stéphanie Ballereau, and Cécile Dehoux. “Multivalent Pyrrolidines Acting as Pharmacological Chaperones against Gaucher Disease.” Bioorganic Chemistry 146 (March 16, 2024): 107295. https://doi.org/10.1016/j.bioorg.2024.107295.
Casasampere, Mireia, Johnson Ung, Alejandro Iñáñez, Carine Duffau, Kazuhito Tsuboi, Josefina Casas, Su-Fern Tan, et al. “A Fluorogenic Substrate for the Detection of Lipid Amidases in Intact Cells.” Journal of Lipid Research, February 16, 2024, 100520. https://doi.org/10.1016/j.jlr.2024.100520.
Krug, Adrien, Marie Tosolini, Blandine Madji Hounoum, Jean-Jacques Fournié, Roger Geiger, Matteo Pecoraro, Patrick Emond, et al. “Inhibition of Choline Metabolism in an Angioimmunoblastic T-Cell Lymphoma Preclinical Model Reveals a New Metabolic Vulnerability as Possible Target for Treatment.” Journal of Experimental & Clinical Cancer Research: CR 43, no. 1 (February 6, 2024): 43. https://doi.org/10.1186/s13046-024-02952-w.
Rives, Clémence, Céline Marie Pauline Martin, Lauris Evariste, Arnaud Polizzi, Marine Huillet, Frédéric Lasserre, Valérie Alquier-Bacquie, et al. “Dietary Amino Acid Source Elicits Sex-Specific Metabolic Response to Diet-Induced NAFLD in Mice.” Molecular Nutrition & Food Research 68, no. 1 (January 2024): e2300491. https://doi.org/10.1002/mnfr.202300491.
Matta, Anthony, Fabienne Ory Magne, Thierry Levade, Fabrice Bonneville, and Jean Ferrières. “Cerebrotendinous Xanthomatosis: A Literature Review and Case Study.” Frontiers in Cardiovascular Medicine 11 (2024): 1496442. https://doi.org/10.3389/fcvm.2024.1496442.
Dufau, Carine, Matthieu Genais, Elodie Mucher, Benjamin Jung, Virginie Garcia, Anne Montfort, Marie Tosolini, et al. “Ceramide Metabolism Alterations Contribute to Tumor Necrosis Factor-Induced Melanoma Dedifferentiation and Predict Resistance to Immune Checkpoint Inhibitors in Advanced Melanoma Patients.” Frontiers in Immunology 15 (2024): 1421432. https://doi.org/10.3389/fimmu.2024.1421432.
PUBLICATIONS 2023
7813506
KC3WFBJR
2023
1
chicago-fullnote-bibliography
50
date
desc
42676
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%227C28CCL6%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Noujar%5Cu00e8de%20et%20al.%22%2C%22parsedDate%22%3A%222023-12-18%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BNoujar%26%23xE8%3Bde%2C%20Justine%2C%20Lorry%20Carri%26%23xE9%3B%2C%20Virginie%20Garcia%2C%20Maxime%20Grimont%2C%20Ana%26%23xEF%3Bs%20Eberhardt%2C%20Elodie%20Mucher%2C%20Matthieu%20Genais%2C%20et%20al.%20%26%23x201C%3BSphingolipid%20Paracrine%20Signaling%20Impairs%20Keratinocyte%20Adhesion%20to%20Promote%20Melanoma%20Invasion.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCell%20Reports%26lt%3B%5C%2Fi%26gt%3B%2042%2C%20no.%2012%20%28December%2018%2C%202023%29%3A%20113586.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.celrep.2023.113586%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.celrep.2023.113586%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Sphingolipid%20paracrine%20signaling%20impairs%20keratinocyte%20adhesion%20to%20promote%20melanoma%20invasion%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justine%22%2C%22lastName%22%3A%22Noujar%5Cu00e8de%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorry%22%2C%22lastName%22%3A%22Carri%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Grimont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%5Cu00efs%22%2C%22lastName%22%3A%22Eberhardt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Mucher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthieu%22%2C%22lastName%22%3A%22Genais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Schreuder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Carpentier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22S%5Cu00e9gui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Nieto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Susana%22%2C%22lastName%22%3A%22Puig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Teresa%22%2C%22lastName%22%3A%22Torres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josep%22%2C%22lastName%22%3A%22Malvehy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Harou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Lopez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Dalle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Caramel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Gibot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jo%5Cu00eblle%22%2C%22lastName%22%3A%22Riond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Andrieu-Abadie%22%7D%5D%2C%22abstractNote%22%3A%22Melanoma%20is%20the%20deadliest%20form%20of%20skin%20cancer%20due%20to%20its%20propensity%20to%20metastasize.%20It%20arises%20from%20melanocytes%2C%20which%20are%20attached%20to%20keratinocytes%20within%20the%20basal%20epidermis.%20Here%2C%20we%20hypothesize%20that%2C%20in%20addition%20to%20melanocyte-intrinsic%20modifications%2C%20dysregulation%20of%20keratinocyte%20functions%20could%20initiate%20early-stage%20melanoma%20cell%20invasion.%20We%20identified%20the%20lysolipid%20sphingosine%201-phosphate%20%28S1P%29%20as%20a%20tumor%20paracrine%20signal%20from%20melanoma%20cells%20that%20modifies%20the%20keratinocyte%20transcriptome%20and%20reduces%20their%20adhesive%20properties%2C%20leading%20to%20tumor%20invasion.%20Mechanistically%2C%20tumor%20cell-derived%20S1P%20reduced%20E-cadherin%20expression%20in%20keratinocytes%20via%20S1P%20receptor%20dependent%20Snail%20and%20Slug%20activation.%20All%20of%20these%20effects%20were%20blocked%20by%20S1P2%5C%2F3%20antagonists.%20Importantly%2C%20we%20showed%20that%20epidermal%20E-cadherin%20expression%20was%20inversely%20correlated%20with%20the%20expression%20of%20the%20S1P-producing%20enzyme%20in%20neighboring%20tumors%20and%20the%20Breslow%20thickness%20in%20patients%20with%20early-stage%20melanoma.%20These%20findings%20support%20the%20notion%20that%20E-cadherin%20loss%20in%20the%20epidermis%20initiates%20the%20metastatic%20cascade%20in%20melanoma.%22%2C%22date%22%3A%222023-12-18%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.celrep.2023.113586%22%2C%22ISSN%22%3A%222211-1247%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222023-12-20T12%3A44%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22PYZBGU84%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tran%20et%20al.%22%2C%22parsedDate%22%3A%222023-09-21%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BTran%2C%20My%20Lan%2C%20Marc%20Borie-Guichot%2C%20Virginie%20Garcia%2C%20Abdelouahd%20Oukhrib%2C%20Yves%20G%26%23xE9%3Bnisson%2C%20Thierry%20Levade%2C%20St%26%23xE9%3Bphanie%20Ballereau%2C%20C%26%23xE9%3Bdric-Olivier%20Turrin%2C%20and%20C%26%23xE9%3Bcile%20Dehoux.%20%26%23x201C%3BPhosphorus%20Dendrimers%20for%20Metal-Free%20Ligation%3A%20Design%20of%20Multivalent%20Pharmacological%20Chaperones%20against%20Gaucher%20Disease.%26%23x201D%3B%20%26lt%3Bi%26gt%3BChemistry%20%28Weinheim%20an%20Der%20Bergstrasse%2C%20Germany%29%26lt%3B%5C%2Fi%26gt%3B%2029%2C%20no.%2053%20%28September%2021%2C%202023%29%3A%20e202301210.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fchem.202301210%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fchem.202301210%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Phosphorus%20Dendrimers%20for%20Metal-Free%20Ligation%3A%20Design%20of%20Multivalent%20Pharmacological%20Chaperones%20against%20Gaucher%20Disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22My%20Lan%22%2C%22lastName%22%3A%22Tran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Borie-Guichot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdelouahd%22%2C%22lastName%22%3A%22Oukhrib%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22G%5Cu00e9nisson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Ballereau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9dric-Olivier%22%2C%22lastName%22%3A%22Turrin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Dehoux%22%7D%5D%2C%22abstractNote%22%3A%22The%20first%20phosphorus%20dendrimers%20built%20on%20a%20cyclotriphosphazene%20core%20and%20decorated%20with%20six%20or%20twelve%20monofluorocyclooctyne%20units%20were%20prepared.%20A%20simple%20stirring%20allowed%20the%20grafting%20of%20N-hexyl%20deoxynojirimycin%20inhitopes%20onto%20their%20surface%20by%20copper-free%20strain%20promoted%20alkyne-azide%20cycloaddition%20click%20reaction.%20The%20synthesized%20iminosugars%20clusters%20were%20tested%20as%20multivalent%20inhibitors%20of%20the%20biologically%20relevant%20enzymes%20%5Cu03b2-glucocerebrosidase%20and%20acid%20%5Cu03b1-glucosidase%2C%20involved%20in%20Gaucher%20and%20Pompe%20lysosomal%20storage%20diseases%2C%20respectively.%20For%20both%20enzymes%2C%20all%20the%20multivalent%20compounds%20were%20more%20potent%20than%20the%20reference%20N-hexyl%20deoxynojirimycin.%20Remarkably%2C%20the%20final%20dodecavalent%20compound%20proved%20to%20be%20one%20of%20the%20best%20%5Cu03b2-glucocerebrosidase%20inhibitors%20described%20to%20date.%20These%20cyclotriphosphazene-based%20deoxynojirimycin%20dendrimers%20were%20then%20evaluated%20as%20pharmacological%20chaperones%20against%20Gaucher%20disease.%20Not%20only%20did%20these%20multivalent%20constructs%20cross%20the%20cell%20membranes%20but%20they%20were%20also%20able%20to%20increase%20%5Cu03b2-glucocerebrosidase%20activity%20in%20Gaucher%20cells.%20Notably%2C%20dodecavalent%20compound%20allowed%20a%201.4-fold%20enzyme%20activity%20enhancement%20at%20a%20concentration%20as%20low%20as%20100%5Cu2005nM.%20These%20new%20monofluorocyclooctyne-presenting%20dendrimers%20may%20further%20find%20numerous%20applications%20in%20the%20synthesis%20of%20multivalent%20objects%20for%20biological%20and%20pharmacological%20purposes.%22%2C%22date%22%3A%222023-09-21%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fchem.202301210%22%2C%22ISSN%22%3A%221521-3765%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222023-09-22T13%3A16%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22UXMW75Y5%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kleynerman%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BKleynerman%2C%20Annie%2C%20Jitka%20Rybova%2C%20Mary%20L.%20Faber%2C%20William%20M.%20McKillop%2C%20Thierry%20Levade%2C%20and%20Jeffrey%20A.%20Medin.%20%26%23x201C%3BAcid%20Ceramidase%20Deficiency%3A%20Bridging%20Gaps%20between%20Clinical%20Presentation%2C%20Mouse%20Models%2C%20and%20Future%20Therapeutic%20Interventions.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBiomolecules%26lt%3B%5C%2Fi%26gt%3B%2013%2C%20no.%202%20%28February%201%2C%202023%29%3A%20274.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fbiom13020274%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fbiom13020274%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Acid%20Ceramidase%20Deficiency%3A%20Bridging%20Gaps%20between%20Clinical%20Presentation%2C%20Mouse%20Models%2C%20and%20Future%20Therapeutic%20Interventions%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annie%22%2C%22lastName%22%3A%22Kleynerman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jitka%22%2C%22lastName%22%3A%22Rybova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mary%20L.%22%2C%22lastName%22%3A%22Faber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%20M.%22%2C%22lastName%22%3A%22McKillop%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%20A.%22%2C%22lastName%22%3A%22Medin%22%7D%5D%2C%22abstractNote%22%3A%22Farber%20disease%20%28FD%29%20and%20spinal%20muscular%20atrophy%20with%20progressive%20myoclonic%20epilepsy%20%28SMA-PME%29%20are%20ultra-rare%2C%20autosomal-recessive%2C%20acid%20ceramidase%20%28ACDase%29%20deficiency%20disorders%20caused%20by%20ASAH1%20gene%20mutations.%20Currently%2C%2073%20different%20mutations%20in%20the%20ASAH1%20gene%20have%20been%20described%20in%20humans.%20These%20mutations%20lead%20to%20reduced%20ACDase%20activity%20and%20ceramide%20%28Cer%29%20accumulation%20in%20many%20tissues.%20Presenting%20as%20divergent%20clinical%20phenotypes%2C%20the%20symptoms%20of%20FD%20vary%20depending%20on%20central%20nervous%20system%20%28CNS%29%20involvement%20and%20severity.%20Classic%20signs%20of%20FD%20include%2C%20but%20are%20not%20limited%20to%2C%20a%20hoarse%20voice%2C%20distended%20joints%2C%20and%20lipogranulomas%20found%20subcutaneously%20and%20in%20other%20tissues.%20Patients%20with%20SMA-PME%20lack%20the%20most%20prominent%20clinical%20signs%20seen%20in%20FD.%20Instead%2C%20they%20demonstrate%20muscle%20weakness%2C%20tremors%2C%20and%20myoclonic%20epilepsy.%20Several%20ACDase-deficient%20mouse%20models%20have%20been%20developed%20to%20help%20elucidate%20the%20complex%20consequences%20of%20Cer%20accumulation.%20In%20this%20review%2C%20we%20compare%20clinical%20reports%20on%20FD%20patients%20and%20experimental%20descriptions%20of%20ACDase-deficient%20mouse%20models.%20We%20also%20discuss%20clinical%20presentations%2C%20potential%20therapeutic%20strategies%2C%20and%20future%20directions%20for%20the%20study%20of%20FD%20and%20SMA-PME.%22%2C%22date%22%3A%222023-02-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fbiom13020274%22%2C%22ISSN%22%3A%222218-273X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222023-03-03T13%3A31%3A30Z%22%7D%7D%5D%7D
Noujarède, Justine, Lorry Carrié, Virginie Garcia, Maxime Grimont, Anaïs Eberhardt, Elodie Mucher, Matthieu Genais, et al. “Sphingolipid Paracrine Signaling Impairs Keratinocyte Adhesion to Promote Melanoma Invasion.” Cell Reports 42, no. 12 (December 18, 2023): 113586. https://doi.org/10.1016/j.celrep.2023.113586.
Tran, My Lan, Marc Borie-Guichot, Virginie Garcia, Abdelouahd Oukhrib, Yves Génisson, Thierry Levade, Stéphanie Ballereau, Cédric-Olivier Turrin, and Cécile Dehoux. “Phosphorus Dendrimers for Metal-Free Ligation: Design of Multivalent Pharmacological Chaperones against Gaucher Disease.” Chemistry (Weinheim an Der Bergstrasse, Germany) 29, no. 53 (September 21, 2023): e202301210. https://doi.org/10.1002/chem.202301210.
Kleynerman, Annie, Jitka Rybova, Mary L. Faber, William M. McKillop, Thierry Levade, and Jeffrey A. Medin. “Acid Ceramidase Deficiency: Bridging Gaps between Clinical Presentation, Mouse Models, and Future Therapeutic Interventions.” Biomolecules 13, no. 2 (February 1, 2023): 274. https://doi.org/10.3390/biom13020274.
PUBLICATIONS 2022
7813506
KC3WFBJR
2022
1
chicago-fullnote-bibliography
50
date
desc
42676
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22XZUNLMLV%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Corrie%20et%20al.%22%2C%22parsedDate%22%3A%222022-12-08%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCorrie%2C%20Pippa%2C%20Nicolas%20Meyer%2C%20Rossana%20Berardi%2C%20Massimo%20Guidoboni%2C%20Maximilian%20Schlueter%2C%20Spyros%20Kolovos%2C%20B%26%23xE9%3Breng%26%23xE8%3Bre%20Macabeo%2C%20Jean-Baptiste%20Trouiller%2C%20and%20Philippe%20Laram%26%23xE9%3Be.%20%26%23x201C%3BErratum%20to%20%26%23x2018%3BComparative%20Efficacy%20and%20Safety%20of%20Targeted%20Therapies%20for%20BRAF-Mutant%20Unresectable%20or%20Metastatic%20Melanoma%3A%20Results%20from%20a%20Systematic%20Literature%20Review%20and%20a%20Network%20Meta-Analysis%26%23x2019%3B%20%5BCancer%20Treat.%20Rev.%20110%20%282022%29%20102463%5D.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancer%20Treatment%20Reviews%26lt%3B%5C%2Fi%26gt%3B%20112%20%28December%208%2C%202022%29%3A%20102495.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ctrv.2022.102495%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ctrv.2022.102495%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Erratum%20to%20%5C%22Comparative%20efficacy%20and%20safety%20of%20targeted%20therapies%20for%20BRAF-mutant%20unresectable%20or%20metastatic%20melanoma%3A%20Results%20from%20a%20systematic%20literature%20review%20and%20a%20network%20meta-analysis%5C%22%20%5BCancer%20Treat.%20Rev.%20110%20%282022%29%20102463%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pippa%22%2C%22lastName%22%3A%22Corrie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rossana%22%2C%22lastName%22%3A%22Berardi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Massimo%22%2C%22lastName%22%3A%22Guidoboni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maximilian%22%2C%22lastName%22%3A%22Schlueter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Spyros%22%2C%22lastName%22%3A%22Kolovos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9reng%5Cu00e8re%22%2C%22lastName%22%3A%22Macabeo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Baptiste%22%2C%22lastName%22%3A%22Trouiller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Laram%5Cu00e9e%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-12-08%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ctrv.2022.102495%22%2C%22ISSN%22%3A%221532-1967%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222022-12-12T12%3A43%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22BJVMLCQB%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lee%20et%20al.%22%2C%22parsedDate%22%3A%222022-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLee%2C%20Michelle%20M.%2C%20Graeme%20S.%20V.%20McDowell%2C%20Darryl%20C.%20De%20Vivo%2C%20Daniel%20Friedman%2C%20Samuel%20F.%20Berkovic%2C%20Maria%20Spanou%2C%20Argirios%20Dinopoulos%2C%20et%20al.%20%26%23x201C%3BThe%20Clinical%20Spectrum%20of%20SMA-PME%20and%20in%26%23xA0%3BVitro%20Normalization%20of%20Its%20Cellular%20Ceramide%20Profile.%26%23x201D%3B%20%26lt%3Bi%26gt%3BAnnals%20of%20Clinical%20and%20Translational%20Neurology%26lt%3B%5C%2Fi%26gt%3B%209%2C%20no.%2012%20%28December%202022%29%3A%201941%26%23x2013%3B52.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Facn3.51687%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Facn3.51687%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20clinical%20spectrum%20of%20SMA-PME%20and%20in%5Cu00a0vitro%20normalization%20of%20its%20cellular%20ceramide%20profile%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michelle%20M.%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Graeme%20S.%20V.%22%2C%22lastName%22%3A%22McDowell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Darryl%20C.%22%2C%22lastName%22%3A%22De%20Vivo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Friedman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%20F.%22%2C%22lastName%22%3A%22Berkovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Spanou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Argirios%22%2C%22lastName%22%3A%22Dinopoulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katheryn%22%2C%22lastName%22%3A%22Grand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pedro%20A.%22%2C%22lastName%22%3A%22Sanchez-Lara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michelle%22%2C%22lastName%22%3A%22Allen-Sharpley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jodi%22%2C%22lastName%22%3A%22Warman-Chardon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Solyom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edward%20H.%22%2C%22lastName%22%3A%22Schuchman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steffany%20A.%20L.%22%2C%22lastName%22%3A%22Bennett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20A.%22%2C%22lastName%22%3A%22Dyment%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Toni%20S.%22%2C%22lastName%22%3A%22Pearson%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20The%20objectives%20of%20this%20study%20were%20to%20define%20the%20clinical%20and%20biochemical%20spectrum%20of%20spinal%20muscular%20atrophy%20with%20progressive%20myoclonic%20epilepsy%20%28SMA-PME%29%20and%20to%20determine%20if%20aberrant%20cellular%20ceramide%20accumulation%20could%20be%20normalized%20by%20enzyme%20replacement.%5CnMETHODS%3A%20Clinical%20features%20of%206%20patients%20with%20SMA-PME%20were%20assessed%20by%20retrospective%20chart%20review%2C%20and%20a%20literature%20review%20of%2024%20previously%20published%20cases%20was%20performed.%20Leukocyte%20enzyme%20activity%20of%20acid%20ceramidase%20was%20assessed%20with%20a%20fluorescence-based%20assay.%20Skin%20fibroblast%20ceramide%20content%20and%20was%20assessed%20by%20high%20performance%20liquid%20chromatography%2C%20electrospray%20ionization%20tandem%20mass%20spectroscopy.%20Enzyme%20replacement%20was%20assessed%20using%20recombinant%20human%20acid%20ceramidase%20%28rhAC%29%20in%5Cu00a0vitro.%5CnRESULTS%3A%20The%20six%20new%20patients%20showed%20the%20hallmark%20features%20of%20SMA-PME%2C%20with%20variable%20initial%20symptom%20and%20age%20of%20onset.%20Five%20of%20six%20patients%20carried%20at%20least%20one%20of%20the%20recurrent%20SMA-PME%20variants%20observed%20in%20two%20specific%20codons%20of%20ASAH1.%20A%20review%20of%2030%20total%20cases%20revealed%20that%20patients%20who%20were%20homozygous%20for%20the%20most%20common%20c.125C%5Cu2009%26gt%3B%5Cu2009T%20variant%20presented%20in%20the%20first%20decade%20of%20life%20with%20limb-girdle%20weakness%20as%20the%20initial%20symptom.%20Sensorineural%20hearing%20loss%20was%20associated%20with%20the%20c.456A%5Cu2009%26gt%3B%5Cu2009C%20variant.%20Leukocyte%20acid%20ceramidase%20activity%20varied%20from%204.1%25-13.1%25%20of%20controls.%20Ceramide%20species%20in%20fibroblasts%20were%20detected%20and%20total%20cellular%20ceramide%20content%20was%20elevated%20by%202%20to%209-fold%20compared%20to%20controls.%20Treatment%20with%20rhAC%20normalized%20ceramide%20profiles%20in%20cultured%20fibroblasts%20to%20control%20levels%20within%2048%5Cu00a0h.%5CnINTERPRETATION%3A%20This%20study%20details%20the%20genotype-phenotype%20correlations%20observed%20in%20SMA-PME%20and%20shows%20the%20impact%20of%20rhAC%20to%20correct%20the%20abnormal%20cellular%20ceramide%20profile%20in%20cells.%22%2C%22date%22%3A%222022-12%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Facn3.51687%22%2C%22ISSN%22%3A%222328-9503%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222022-12-19T09%3A47%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22A8A76IKF%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Carrier%20et%20al.%22%2C%22parsedDate%22%3A%222022-11-28%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCarrier%2C%20Arnaud%2C%20C%26%23xE9%3Bcile%20Desjobert%2C%20Val%26%23xE9%3Brie%20Lobjois%2C%20Lise%20Rigal%2C%20Florence%20Busato%2C%20J%26%23xF6%3Brg%20Tost%2C%20Miquel%20Ensenyat-Mendez%2C%20et%20al.%20%26%23x201C%3BEpigenetically%20Regulated%20PCDHB15%20Impairs%20Aggressiveness%20of%20Metastatic%20Melanoma%20Cells.%26%23x201D%3B%20%26lt%3Bi%26gt%3BClinical%20Epigenetics%26lt%3B%5C%2Fi%26gt%3B%2014%2C%20no.%201%20%28November%2028%2C%202022%29%3A%20156.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13148-022-01364-x%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs13148-022-01364-x%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Epigenetically%20regulated%20PCDHB15%20impairs%20aggressiveness%20of%20metastatic%20melanoma%20cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Carrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Desjobert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Lobjois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lise%22%2C%22lastName%22%3A%22Rigal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Busato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00f6rg%22%2C%22lastName%22%3A%22Tost%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miquel%22%2C%22lastName%22%3A%22Ensenyat-Mendez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diego%20M.%22%2C%22lastName%22%3A%22Marzese%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Pradines%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Favre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Lamant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luisa%22%2C%22lastName%22%3A%22Lanfrancone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Etievant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paola%20B.%22%2C%22lastName%22%3A%22Arimondo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jo%5Cu00eblle%22%2C%22lastName%22%3A%22Riond%22%7D%5D%2C%22abstractNote%22%3A%22The%20protocadherin%20proteins%20are%20cell%20adhesion%20molecules%20at%20the%20crossroad%20of%20signaling%20pathways%20playing%20a%20major%20role%20in%20neuronal%20development.%20It%20is%20now%20understood%20that%20their%20role%20as%20signaling%20hubs%20is%20not%20only%20important%20for%20the%20normal%20physiology%20of%20cells%20but%20also%20for%20the%20regulation%20of%20hallmarks%20of%20cancerogenesis.%20Importantly%2C%20protocadherins%20form%20a%20cluster%20of%20genes%20that%20are%20regulated%20by%20DNA%20methylation.%20We%20have%20identified%20for%20the%20first%20time%20that%20PCDHB15%20gene%20is%20DNA-hypermethylated%20on%20its%20unique%20exon%20in%20the%20metastatic%20melanoma-derived%20cell%20lines%20and%20patients%26%23039%3B%20metastases%20compared%20to%20primary%20tumors.%20This%20DNA%20hypermethylation%20silences%20the%20gene%2C%20and%20treatment%20with%20the%20DNA%20demethylating%20agent%205-aza-2%26%23039%3B-deoxycytidine%20reinduces%20its%20expression.%20We%20explored%20the%20role%20of%20PCDHB15%20in%20melanoma%20aggressiveness%20and%20showed%20that%20overexpression%20impairs%20invasiveness%20and%20aggregation%20of%20metastatic%20melanoma%20cells%20in%20vitro%20and%20formation%20of%20lung%20metastasis%20in%20vivo.%20These%20findings%20highlight%20important%20modifications%20of%20the%20methylation%20of%20the%20PCDH%5Cu03b2%20genes%20in%20melanoma%20and%20support%20a%20functional%20role%20of%20PCDHB15%20silencing%20in%20melanoma%20aggressiveness.%22%2C%22date%22%3A%222022-11-28%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs13148-022-01364-x%22%2C%22ISSN%22%3A%221868-7083%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22W973EZ5X%22%2C%22VDZ48X5N%22%2C%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222024-02-13T10%3A17%3A06Z%22%7D%7D%2C%7B%22key%22%3A%229JSQNBQ6%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Corrie%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-22%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCorrie%2C%20Pippa%2C%20Nicolas%20Meyer%2C%20Rossana%20Berardi%2C%20Massimo%20Guidoboni%2C%20Max%20Schlueter%2C%20Spyros%20Kolovos%2C%20B%26%23xE9%3Breng%26%23xE8%3Bre%20Macabeo%2C%20Jean-Baptiste%20Trouiller%2C%20and%20Philippe%20Laram%26%23xE9%3Be.%20%26%23x201C%3BResponse%20to%20%26%23x2018%3BConsiderations%20Regarding%20a%20Network%20Meta-Analysis%20of%20Targeted%20Therapies%20for%20BRAF%20Mutant%20Unresectable%20or%20Metastatic%20Melanoma.%26%23x2019%3B%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancer%20Treatment%20Reviews%26lt%3B%5C%2Fi%26gt%3B%20111%20%28October%2022%2C%202022%29%3A%20102478.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ctrv.2022.102478%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ctrv.2022.102478%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Response%20to%20%27considerations%20regarding%20a%20network%20meta-analysis%20of%20targeted%20therapies%20for%20BRAF%20mutant%20unresectable%20or%20metastatic%20melanoma%27%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pippa%22%2C%22lastName%22%3A%22Corrie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rossana%22%2C%22lastName%22%3A%22Berardi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Massimo%22%2C%22lastName%22%3A%22Guidoboni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Max%22%2C%22lastName%22%3A%22Schlueter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Spyros%22%2C%22lastName%22%3A%22Kolovos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9reng%5Cu00e8re%22%2C%22lastName%22%3A%22Macabeo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Baptiste%22%2C%22lastName%22%3A%22Trouiller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Laram%5Cu00e9e%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-10-22%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ctrv.2022.102478%22%2C%22ISSN%22%3A%221532-1967%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222022-11-02T09%3A47%3A18Z%22%7D%7D%2C%7B%22key%22%3A%22WQWJF8K3%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dubot%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-05%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDubot%2C%20Patricia%2C%20Leonardo%20Astudillo%2C%20Nicole%20Therville%2C%20Lorry%20Carri%26%23xE9%3B%2C%20Magali%20Pettazzoni%2C%20David%20Cheillan%2C%20J%26%23xE9%3Br%26%23xF4%3Bme%20Stirnemann%2C%20Thierry%20Levade%2C%20Nathalie%20Andrieu-Abadie%2C%20and%20Fr%26%23xE9%3Bd%26%23xE9%3Brique%20Sabourdy.%20%26%23x201C%3BPotential%20Role%20of%20Sphingolipidoses-Associated%20Lysosphingolipids%20in%20Cancer.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancers%26lt%3B%5C%2Fi%26gt%3B%2014%2C%20no.%2019%20%28October%205%2C%202022%29%3A%204858.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers14194858%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers14194858%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Potential%20Role%20of%20Sphingolipidoses-Associated%20Lysosphingolipids%20in%20Cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Dubot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leonardo%22%2C%22lastName%22%3A%22Astudillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicole%22%2C%22lastName%22%3A%22Therville%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorry%22%2C%22lastName%22%3A%22Carri%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magali%22%2C%22lastName%22%3A%22Pettazzoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Cheillan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Stirnemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Andrieu-Abadie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9rique%22%2C%22lastName%22%3A%22Sabourdy%22%7D%5D%2C%22abstractNote%22%3A%22Sphingolipids%20play%20a%20key%20structural%20role%20in%20cellular%20membranes%20and%5C%2For%20act%20as%20signaling%20molecules.%20Inherited%20defects%20of%20their%20catabolism%20lead%20to%20lysosomal%20storage%20diseases%20called%20sphingolipidoses.%20Although%20progress%20has%20been%20made%20toward%20a%20better%20understanding%20of%20their%20pathophysiology%2C%20several%20issues%20still%20remain%20unsolved.%20In%20particular%2C%20whether%20lysosphingolipids%2C%20the%20deacylated%20form%20of%20sphingolipids%2C%20both%20of%20which%20accumulate%20in%20these%20diseases%2C%20are%20simple%20biomarkers%20or%20play%20an%20instrumental%20role%20is%20unclear.%20In%20the%20meanwhile%2C%20evidence%20has%20been%20provided%20for%20a%20high%20risk%20of%20developing%20malignancies%20in%20patients%20affected%20with%20Gaucher%20disease%2C%20the%20most%20common%20sphingolipidosis.%20This%20article%20aims%20at%20analyzing%20the%20potential%20involvement%20of%20lysosphingolipids%20in%20cancer.%20Knowledge%20about%20lysosphingolipids%20in%20the%20context%20of%20lysosomal%20storage%20diseases%20is%20summarized.%20Available%20data%20on%20the%20nature%20and%20prevalence%20of%20cancers%20in%20patients%20affected%20with%20sphingolipidoses%20are%20also%20reviewed.%20Then%2C%20studies%20investigating%20the%20biological%20effects%20of%20lysosphingolipids%20toward%20pro%20or%20antitumor%20pathways%20are%20discussed.%20Finally%2C%20original%20findings%20exploring%20the%20role%20of%20glucosylsphingosine%20in%20the%20development%20of%20melanoma%20are%20presented.%20While%20this%20lysosphingolipid%20may%20behave%20like%20a%20protumorigenic%20agent%2C%20further%20investigations%20in%20appropriate%20models%20are%20needed%20to%20elucidate%20the%20role%20of%20these%20peculiar%20lipids%2C%20not%20only%20in%20sphingolipidoses%20but%20also%20in%20malignant%20diseases%20in%20general.%22%2C%22date%22%3A%222022-10-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers14194858%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222022-10-25T10%3A36%3A47Z%22%7D%7D%2C%7B%22key%22%3A%229A6M78D5%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Carrier%20et%20al.%22%2C%22parsedDate%22%3A%222022-09-20%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCarrier%2C%20Arnaud%2C%20C%26%23xE9%3Bcile%20Desjobert%2C%20Loic%20Ponger%2C%20Laurence%20Lamant%2C%20Matias%20Bustos%2C%20Jorge%20Torres-Ferreira%2C%20Rui%20Henrique%2C%20et%20al.%20%26%23x201C%3BDNA%20Methylome%20Combined%20with%20Chromosome%20Cluster-Oriented%20Analysis%20Provides%20an%20Early%20Signature%20for%20Cutaneous%20Melanoma%20Aggressiveness.%26%23x201D%3B%20%26lt%3Bi%26gt%3BeLife%26lt%3B%5C%2Fi%26gt%3B%2011%20%28September%2020%2C%202022%29%3A%20e78587.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7554%5C%2FeLife.78587%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.7554%5C%2FeLife.78587%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22DNA%20methylome%20combined%20with%20chromosome%20cluster-oriented%20analysis%20provides%20an%20early%20signature%20for%20cutaneous%20melanoma%20aggressiveness%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Carrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Desjobert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Ponger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Lamant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matias%22%2C%22lastName%22%3A%22Bustos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Torres-Ferreira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rui%22%2C%22lastName%22%3A%22Henrique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carmen%22%2C%22lastName%22%3A%22Jeronimo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luisa%22%2C%22lastName%22%3A%22Lanfrancone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Delmas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Favre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Daunay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Busato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dave%20S.%20B.%22%2C%22lastName%22%3A%22Hoon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorg%22%2C%22lastName%22%3A%22Tost%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Etievant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jo%5Cu00eblle%22%2C%22lastName%22%3A%22Riond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paola%20B.%22%2C%22lastName%22%3A%22Arimondo%22%7D%5D%2C%22abstractNote%22%3A%22Aberrant%20DNA%20methylation%20is%20a%20well-known%20feature%20of%20tumours%20and%20has%20been%20associated%20with%20metastatic%20melanoma.%20However%2C%20since%20melanoma%20cells%20are%20highly%20heterogeneous%2C%20it%20has%20been%20challenging%20to%20use%20affected%20genes%20to%20predict%20tumour%20aggressiveness%2C%20metastatic%20evolution%2C%20and%20patients%26%23039%3B%20outcomes.%20We%20hypothesized%20that%20common%20aggressive%20hypermethylation%20signatures%20should%20emerge%20early%20in%20tumorigenesis%20and%20should%20be%20shared%20in%20aggressive%20cells%2C%20independent%20of%20the%20physiological%20context%20under%20which%20this%20trait%20arises.%20We%20compared%20paired%20melanoma%20cell%20lines%20with%20the%20following%20properties%3A%20%28i%29%20each%20pair%20comprises%20one%20aggressive%20counterpart%20and%20its%20parental%20cell%20line%20and%20%28ii%29%20the%20aggressive%20cell%20lines%20were%20each%20obtained%20from%20different%20host%20and%20their%20environment%20%28human%2C%20rat%2C%20and%20mouse%29%2C%20though%20starting%20from%20the%20same%20parent%20cell%20line.%20Next%2C%20we%20developed%20a%20multi-step%20genomic%20pipeline%20that%20combines%20the%20DNA%20methylome%20profile%20with%20a%20chromosome%20cluster-oriented%20analysis.%20A%20total%20of%20229%20differentially%20hypermethylated%20genes%20was%20commonly%20found%20in%20the%20aggressive%20cell%20lines.%20Genome%20localization%20analysis%20revealed%20hypermethylation%20peaks%20and%20clusters%2C%20identifying%20eight%20hypermethylated%20gene%20promoters%20for%20validation%20in%20tissues%20from%20melanoma%20patients.%20Five%20Cytosine-phosphate-Guanine%20%28CpGs%29%20identified%20in%20primary%20melanoma%20tissues%20were%20transformed%20into%20a%20DNA%20methylation%20score%20that%20can%20predict%20survival%20%28log-rank%20test%2C%20p%3D0.0008%29.%20This%20strategy%20is%20potentially%20universally%20applicable%20to%20other%20diseases%20involving%20DNA%20methylation%20alterations.%22%2C%22date%22%3A%222022-09-20%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.7554%5C%2FeLife.78587%22%2C%22ISSN%22%3A%222050-084X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22W973EZ5X%22%2C%22VDZ48X5N%22%2C%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222023-01-04T10%3A19%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22ERHS888L%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lazar%20et%20al.%22%2C%22parsedDate%22%3A%222022-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLazar%2C%20Ikrame%2C%20Emily%20Clement%2C%20Lorry%20Carri%26%23xE9%3B%2C%20David%20Esteve%2C%20St%26%23xE9%3Bphanie%20Dauvillier%2C%20Mohamed%20Moutahir%2C%20St%26%23xE9%3Bphane%20Dalle%2C%20et%20al.%20%26%23x201C%3BAdipocyte%20Extracellular%20Vesicles%20Decrease%20p16INK4A%20in%20Melanoma%3A%20An%20Additional%20Link%20between%20Obesity%20and%20Cancer.%26%23x201D%3B%20%26lt%3Bi%26gt%3BThe%20Journal%20of%20Investigative%20Dermatology%26lt%3B%5C%2Fi%26gt%3B%20142%2C%20no.%209%20%28September%202022%29%3A%202488-2498.e8.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jid.2022.01.026%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jid.2022.01.026%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Adipocyte%20Extracellular%20Vesicles%20Decrease%20p16INK4A%20in%20Melanoma%3A%20An%20Additional%20Link%20between%20Obesity%20and%20Cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ikrame%22%2C%22lastName%22%3A%22Lazar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emily%22%2C%22lastName%22%3A%22Clement%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorry%22%2C%22lastName%22%3A%22Carri%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Esteve%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Dauvillier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohamed%22%2C%22lastName%22%3A%22Moutahir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Dalle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Delmas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Andrieu-Abadie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lionel%22%2C%22lastName%22%3A%22Larue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Muller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Nieto%22%7D%5D%2C%22abstractNote%22%3A%22Obesity%20is%20a%20recognized%20factor%20for%20increased%20risk%20and%20poor%20prognosis%20of%20many%20cancers%2C%20including%20melanoma.%20In%20this%20study%2C%20using%20genetically%20engineered%20mouse%20models%20of%20melanoma%20%28NrasQ61K%20transgenic%20expression%2C%20associated%20or%20not%20with%20Cdkn2a%20heterozygous%20deletion%29%2C%20we%20show%20that%20obesity%20increases%20melanoma%20initiation%20and%20progression%20by%20supporting%20tumor%20growth%20and%20metastasis%2C%20thereby%20reducing%20survival.%20This%20effect%20is%20associated%20with%20a%20decrease%20in%20p16INK4A%20expression%20in%20tumors.%20Mechanistically%2C%20adipocytes%20downregulate%20p16INK4A%20in%20melanoma%20cells%20through%20%5Cu03b2-catenin-dependent%20regulation%2C%20which%20increases%20cell%20motility.%20Furthermore%2C%20%5Cu03b2-catenin%20is%20directly%20transferred%20from%20adipocytes%20to%20melanoma%20cells%20in%20extracellular%20vesicles%2C%20thus%20increasing%20its%20level%20and%20activity%2C%20which%20represses%20CDKN2A%20transcription.%20Adipocytes%20from%20individuals%20with%20obesity%20have%20a%20stronger%20effect%20than%20those%20from%20lean%20individuals%2C%20mainly%20owing%20to%20an%20increase%20in%20the%20number%20of%20vesicles%20secreted%2C%20thus%20increasing%20the%20amount%20of%20%5Cu03b2-catenin%20delivered%20to%20melanoma%20cells%20and%2C%20consequently%2C%20amplifying%20their%20effect.%20In%20conclusion%2C%20in%20this%20study%2C%20we%20reveal%20that%20adipocyte%20extracellular%20vesicles%20control%20p16INK4A%20expression%20in%20melanoma%2C%20which%20promotes%20tumor%20progression.%20This%20work%20expands%20our%20understanding%20of%20the%20cooperation%20between%20adipocytes%20and%20tumors%2C%20particularly%20in%20obesity.%22%2C%22date%22%3A%222022-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jid.2022.01.026%22%2C%22ISSN%22%3A%221523-1747%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222022-08-25T07%3A22%3A55Z%22%7D%7D%2C%7B%22key%22%3A%22IV4QYAMW%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Fougerat%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFougerat%2C%20Anne%2C%20Gabriele%20Schoiswohl%2C%20Arnaud%20Polizzi%2C%20Marion%20R%26%23xE9%3Bgnier%2C%20Carina%20Wagner%2C%20Sarra%20Smati%2C%20Tiffany%20Fougeray%2C%20et%20al.%20%26%23x201C%3BATGL-Dependent%20White%20Adipose%20Tissue%20Lipolysis%20Controls%20Hepatocyte%20PPAR%26%23x3B1%3B%20Activity.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCell%20Reports%26lt%3B%5C%2Fi%26gt%3B%2039%2C%20no.%2010%20%28June%207%2C%202022%29%3A%20110910.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.celrep.2022.110910%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.celrep.2022.110910%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22ATGL-dependent%20white%20adipose%20tissue%20lipolysis%20controls%20hepatocyte%20PPAR%5Cu03b1%20activity%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Fougerat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriele%22%2C%22lastName%22%3A%22Schoiswohl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Polizzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22R%5Cu00e9gnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carina%22%2C%22lastName%22%3A%22Wagner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarra%22%2C%22lastName%22%3A%22Smati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tiffany%22%2C%22lastName%22%3A%22Fougeray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yannick%22%2C%22lastName%22%3A%22Lippi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Lasserre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ily%5Cu00e8s%22%2C%22lastName%22%3A%22Raho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valentine%22%2C%22lastName%22%3A%22Melin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Blandine%22%2C%22lastName%22%3A%22Tramunt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rapha%5Cu00ebl%22%2C%22lastName%22%3A%22M%5Cu00e9tivier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Sommer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fadila%22%2C%22lastName%22%3A%22Benhamed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Alkhoury%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franziska%22%2C%22lastName%22%3A%22Greulich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Jouffe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Emile%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Schupp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Gourdy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Dubot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Meynard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Ellero-Simatos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Gamet-Payrastre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ganna%22%2C%22lastName%22%3A%22Panasyuk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Henriette%22%2C%22lastName%22%3A%22Uhlenhaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ez-Zoubir%22%2C%22lastName%22%3A%22Amri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Cruciani-Guglielmacci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Postic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Walter%22%2C%22lastName%22%3A%22Wahli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Loiseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Montagner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Langin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Achim%22%2C%22lastName%22%3A%22Lass%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Guillou%22%7D%5D%2C%22abstractNote%22%3A%22In%20hepatocytes%2C%20peroxisome%20proliferator-activated%20receptor%20%5Cu03b1%20%28PPAR%5Cu03b1%29%20orchestrates%20a%20genomic%20and%20metabolic%20response%20required%20for%20homeostasis%20during%20fasting.%20This%20includes%20the%20biosynthesis%20of%20ketone%20bodies%20and%20of%20fibroblast%20growth%20factor%2021%20%28FGF21%29.%20Here%20we%20show%20that%20in%20the%20absence%20of%20adipose%20triglyceride%20lipase%20%28ATGL%29%20in%20adipocytes%2C%20ketone%20body%20and%20FGF21%20production%20is%20impaired%20upon%20fasting.%20Liver%20gene%20expression%20analysis%20highlights%20a%20set%20of%20fasting-induced%20genes%20sensitive%20to%20both%20ATGL%20deletion%20in%20adipocytes%20and%20PPAR%5Cu03b1%20deletion%20in%20hepatocytes.%20Adipose%20tissue%20lipolysis%20induced%20by%20activation%20of%20the%20%5Cu03b23-adrenergic%20receptor%20also%20triggers%20such%20PPAR%5Cu03b1-dependent%20responses%20not%20only%20in%20the%20liver%20but%20also%20in%20brown%20adipose%20tissue%20%28BAT%29.%20Intact%20PPAR%5Cu03b1%20activity%20in%20hepatocytes%20is%20required%20for%20the%20cross-talk%20between%20adipose%20tissues%20and%20the%20liver%20during%20fat%20mobilization.%22%2C%22date%22%3A%222022-06-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.celrep.2022.110910%22%2C%22ISSN%22%3A%222211-1247%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222022-06-13T10%3A39%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22U4CF5BWV%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Germain%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGermain%2C%20Dominique%20P.%2C%20Thierry%20Levade%2C%20Eric%20Hachulla%2C%20Bertrand%20Knebelmann%2C%20Didier%20Lacombe%2C%20Vanessa%20Leguy%20Seguin%2C%20Karine%20Nguyen%2C%20Esther%20No%26%23xEB%3Bl%2C%20and%20Jean-Pierre%20Rab%26%23xE8%3Bs.%20%26%23x201C%3BChallenging%20the%20Traditional%20Approach%20for%20Interpreting%20Genetic%20Variants%3A%20Lessons%20from%20Fabry%20Disease.%26%23x201D%3B%20%26lt%3Bi%26gt%3BClinical%20Genetics%26lt%3B%5C%2Fi%26gt%3B%20101%2C%20no.%204%20%28April%202022%29%3A%20390%26%23x2013%3B402.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fcge.14102%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fcge.14102%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Challenging%20the%20traditional%20approach%20for%20interpreting%20genetic%20variants%3A%20Lessons%20from%20Fabry%20disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%20P.%22%2C%22lastName%22%3A%22Germain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Hachulla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Knebelmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Lacombe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%20Leguy%22%2C%22lastName%22%3A%22Seguin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karine%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Esther%22%2C%22lastName%22%3A%22No%5Cu00ebl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Rab%5Cu00e8s%22%7D%5D%2C%22abstractNote%22%3A%22Fabry%20disease%20%28FD%29%20is%20an%20X-linked%20genetic%20disease%20due%20to%20pathogenic%20variants%20in%20GLA.%20The%20phenotype%20varies%20depending%20on%20the%20GLA%20variant%2C%20alpha-galactosidase%20residual%20activity%2C%20patient%26%23039%3Bs%20age%20and%20gender%20and%2C%20for%20females%2C%20X%20chromosome%20inactivation.%20Over%201000%20variants%20have%20been%20identified%2C%20many%20through%20screening%20protocols%20more%20susceptible%20to%20disclose%20non-pathogenic%20variants%20or%20variants%20of%20unknown%20significance%20%28VUS%29.%20This%2C%20together%20with%20the%20non-specificity%20of%20some%20FD%20symptoms%2C%20challenges%20physicians%20attempting%20to%20interpret%20GLA%20variants.%20The%20traditional%20way%20to%20interpreting%20pathogenicity%20is%20based%20on%20a%20combined%20approach%20using%20allele%20frequencies%2C%20genomic%20databases%2C%20global%20and%20disease-specific%20clinical%20databases%2C%20and%20in%20silico%20tools%20proposed%20by%20the%20American%20College%20of%20Medical%20Genetics%20and%20Genomics.%20Here%2C%20a%20panel%20of%20FD%20specialists%20convened%20to%20study%20how%20expertise%20may%20compare%20with%20the%20traditional%20approach.%20Several%20GLA%20VUS%2C%20highly%20controversial%20in%20the%20literature%20%28p.Ser126Gly%2C%20p.Ala143Thr%2C%20p.Asp313Tyr%29%2C%20were%20re-analyzed%20through%20reviews%20of%20patients%26%23039%3B%20charts.%20The%20same%20was%20done%20for%20pathogenic%20GLA%20variants%20with%20some%20specificities.%20Our%20data%20suggest%20that%20input%20of%20geneticists%20and%20physicians%20with%20wide%20expertise%20in%20disease%20phenotypes%2C%20prevalence%2C%20inheritance%2C%20biomarkers%2C%20alleles%20frequencies%2C%20disease-specific%20databases%2C%20and%20literature%20greatly%20contribute%20to%20a%20more%20accurate%20interpretation%20of%20the%20pathogenicity%20of%20variants%2C%20bringing%20a%20significant%20additional%20value%20over%20the%20traditional%20approach.%22%2C%22date%22%3A%222022-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fcge.14102%22%2C%22ISSN%22%3A%221399-0004%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A09%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22YMP6IJRR%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dummer%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-14%22%2C%22numChildren%22%3A7%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDummer%2C%20Reinhard%2C%20Georgina%20V.%20Long%2C%20Caroline%20Robert%2C%20Hussein%20A.%20Tawbi%2C%20Keith%20T.%20Flaherty%2C%20Paolo%20A.%20Ascierto%2C%20Paul%20D.%20Nathan%2C%20et%20al.%20%26%23x201C%3BRandomized%20Phase%20III%20Trial%20Evaluating%20Spartalizumab%20Plus%20Dabrafenib%20and%20Trametinib%20for%20BRAF%20V600-Mutant%20Unresectable%20or%20Metastatic%20Melanoma.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Clinical%20Oncology%3A%20Official%20Journal%20of%20the%20American%20Society%20of%20Clinical%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2C%20January%2014%2C%202022%2C%20JCO2101601.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1200%5C%2FJCO.21.01601%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1200%5C%2FJCO.21.01601%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Randomized%20Phase%20III%20Trial%20Evaluating%20Spartalizumab%20Plus%20Dabrafenib%20and%20Trametinib%20for%20BRAF%20V600-Mutant%20Unresectable%20or%20Metastatic%20Melanoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Reinhard%22%2C%22lastName%22%3A%22Dummer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georgina%20V.%22%2C%22lastName%22%3A%22Long%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hussein%20A.%22%2C%22lastName%22%3A%22Tawbi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keith%20T.%22%2C%22lastName%22%3A%22Flaherty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paolo%20A.%22%2C%22lastName%22%3A%22Ascierto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%20D.%22%2C%22lastName%22%3A%22Nathan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Piotr%22%2C%22lastName%22%3A%22Rutkowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oleg%22%2C%22lastName%22%3A%22Leonov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Dutriaux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mario%22%2C%22lastName%22%3A%22Mandal%5Cu00e0%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Lorigan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pier%20Francesco%22%2C%22lastName%22%3A%22Ferrucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Jacques%22%2C%22lastName%22%3A%22Grob%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helen%22%2C%22lastName%22%3A%22Gogas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniil%22%2C%22lastName%22%3A%22Stroyakovskiy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%22%2C%22lastName%22%3A%22Arance%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20C.%22%2C%22lastName%22%3A%22Brase%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%22%2C%22lastName%22%3A%22Green%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomas%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aisha%22%2C%22lastName%22%3A%22Masood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduard%22%2C%22lastName%22%3A%22Gasal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoni%22%2C%22lastName%22%3A%22Ribas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dirk%22%2C%22lastName%22%3A%22Schadendorf%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20Preclinical%20data%20suggest%20the%20combination%20of%20an%20anti-programmed%20death%20receptor%201%20antibody%20plus%20dabrafenib%20and%20trametinib%20to%20have%20superior%20antitumor%20activity%20compared%20with%20dabrafenib%20plus%20trametinib%20alone.%20These%20observations%20are%20supported%20by%20translational%20evidence%20suggesting%20that%20immune%20checkpoint%20inhibitors%20plus%20targeted%20therapy%20may%20improve%20treatment%20outcomes%20in%20patients%20with%20BRAF%20V600-mutant%20metastatic%20melanoma.%20COMBI-i%20is%20a%20phase%20III%20trial%20evaluating%20spartalizumab%2C%20an%20anti-programmed%20death%20receptor%201%20antibody%2C%20in%20combination%20with%20dabrafenib%20and%20trametinib%20%28sparta-DabTram%29%2C%20versus%20placebo%20plus%20dabrafenib%20and%20trametinib%20%28placebo-DabTram%29%20in%20patients%20with%20BRAF%20V600-mutant%20unresectable%20or%20metastatic%20melanoma.%5CnMETHODS%3A%20Patients%20received%20spartalizumab%20400%20mg%20intravenously%20every%204%20weeks%20plus%20dabrafenib%20150%20mg%20orally%20twice%20daily%20and%20trametinib%202%20mg%20orally%20once%20daily%20or%20placebo-DabTram.%20Participants%20were%20age%20%5Cu2265%2018%20years%20with%20unresectable%20or%20metastatic%20BRAF%20V600-mutant%20melanoma.%20The%20primary%20end%20point%20was%20investigator-assessed%20progression-free%20survival.%20Overall%20survival%20was%20a%20key%20secondary%20end%20point%20%28ClinicalTrials.gov%20identifier%3A%20NCT02967692%29.%5CnRESULTS%3A%20At%20data%20cutoff%20%28July%201%2C%202020%29%2C%20the%20median%20progression-free%20survival%20was%2016.2%20months%20%2895%25%20CI%2C%2012.7%20to%2023.9%20months%29%20in%20the%20sparta-DabTram%20arm%20versus%2012.0%20months%20%2895%25%20CI%2C%2010.2%20to%2015.4%20months%29%20in%20the%20placebo-DabTram%20arm%20%28hazard%20ratio%2C%200.82%20%5B95%25%20CI%2C%200.66%20to%201.03%5D%3B%20P%20%3D%20.042%20%5Bone-sided%3B%20nonsignificant%5D%29.%20The%20objective%20response%20rates%20were%2069%25%20%28183%20of%20267%20patients%29%20versus%2064%25%20%28170%20of%20265%20patients%29%2C%20respectively.%20Grade%20%5Cu2265%203%20treatment-related%20adverse%20events%20occurred%20in%2055%25%20%28146%20of%20267%29%20of%20patients%20in%20the%20sparta-DabTram%20arm%20and%2033%25%20%2888%20of%20264%29%20in%20the%20placebo-DabTram%20arm.%5CnCONCLUSION%3A%20The%20study%20did%20not%20meet%20its%20primary%20end%20point%3B%20broad%20first-line%20use%20of%20sparta-DabTram%20is%20not%20supported%20by%20these%20results.%20Further%20biomarker-driven%20investigation%20may%20identify%20patient%20subpopulations%20who%20could%20benefit%20from%20checkpoint%20inhibitor%20plus%20targeted%20therapy%20combinations.%22%2C%22date%22%3A%222022-01-14%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1200%5C%2FJCO.21.01601%22%2C%22ISSN%22%3A%221527-7755%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%223U3NWA3K%22%2C%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A11%3A05Z%22%7D%7D%2C%7B%22key%22%3A%224QBIPBIM%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pippa%20et%20al.%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPippa%2C%20Corrie%2C%20Meyer%20Nicolas%2C%20Berardi%20Rossana%2C%20Guidoboni%20Massimo%2C%20Schlueter%20Maximilian%2C%20Kolovos%20Spyros%2C%20Macabeo%20B%26%23xE9%3Breng%26%23xE8%3Bre%2C%20Trouiller%20Jean-Baptiste%2C%20and%20Laram%26%23xE9%3Be%20Philippe.%20%26%23x201C%3BComparative%20Efficacy%20and%20Safety%20of%20Targeted%20Therapies%20for%20BRAF-Mutant%20Unresectable%20or%20Metastatic%20Melanoma%3A%20Results%20from%20a%20Systematic%20Literature%20Review%20and%20a%20Network%20Meta-Analysis.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancer%20Treatment%20Reviews%26lt%3B%5C%2Fi%26gt%3B%20110%20%282022%29%3A%20102463.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ctrv.2022.102463%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ctrv.2022.102463%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comparative%20efficacy%20and%20safety%20of%20targeted%20therapies%20for%20BRAF-mutant%20unresectable%20or%20metastatic%20melanoma%3A%20Results%20from%20a%20systematic%20literature%20review%20and%20a%20network%20meta-analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corrie%22%2C%22lastName%22%3A%22Pippa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meyer%22%2C%22lastName%22%3A%22Nicolas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Berardi%22%2C%22lastName%22%3A%22Rossana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guidoboni%22%2C%22lastName%22%3A%22Massimo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Schlueter%22%2C%22lastName%22%3A%22Maximilian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kolovos%22%2C%22lastName%22%3A%22Spyros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Macabeo%22%2C%22lastName%22%3A%22B%5Cu00e9reng%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Trouiller%22%2C%22lastName%22%3A%22Jean-Baptiste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laram%5Cu00e9e%22%2C%22lastName%22%3A%22Philippe%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2211%5C%2F2022%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ctrv.2022.102463%22%2C%22ISSN%22%3A%2203057372%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS0305737222001323%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222022-09-19T10%3A51%3A53Z%22%7D%7D%5D%7D
Corrie, Pippa, Nicolas Meyer, Rossana Berardi, Massimo Guidoboni, Maximilian Schlueter, Spyros Kolovos, Bérengère Macabeo, Jean-Baptiste Trouiller, and Philippe Laramée. “Erratum to ‘Comparative Efficacy and Safety of Targeted Therapies for BRAF-Mutant Unresectable or Metastatic Melanoma: Results from a Systematic Literature Review and a Network Meta-Analysis’ [Cancer Treat. Rev. 110 (2022) 102463].” Cancer Treatment Reviews 112 (December 8, 2022): 102495. https://doi.org/10.1016/j.ctrv.2022.102495.
Lee, Michelle M., Graeme S. V. McDowell, Darryl C. De Vivo, Daniel Friedman, Samuel F. Berkovic, Maria Spanou, Argirios Dinopoulos, et al. “The Clinical Spectrum of SMA-PME and in Vitro Normalization of Its Cellular Ceramide Profile.” Annals of Clinical and Translational Neurology 9, no. 12 (December 2022): 1941–52. https://doi.org/10.1002/acn3.51687.
Carrier, Arnaud, Cécile Desjobert, Valérie Lobjois, Lise Rigal, Florence Busato, Jörg Tost, Miquel Ensenyat-Mendez, et al. “Epigenetically Regulated PCDHB15 Impairs Aggressiveness of Metastatic Melanoma Cells.” Clinical Epigenetics 14, no. 1 (November 28, 2022): 156. https://doi.org/10.1186/s13148-022-01364-x.
Corrie, Pippa, Nicolas Meyer, Rossana Berardi, Massimo Guidoboni, Max Schlueter, Spyros Kolovos, Bérengère Macabeo, Jean-Baptiste Trouiller, and Philippe Laramée. “Response to ‘Considerations Regarding a Network Meta-Analysis of Targeted Therapies for BRAF Mutant Unresectable or Metastatic Melanoma.’” Cancer Treatment Reviews 111 (October 22, 2022): 102478. https://doi.org/10.1016/j.ctrv.2022.102478.
Dubot, Patricia, Leonardo Astudillo, Nicole Therville, Lorry Carrié, Magali Pettazzoni, David Cheillan, Jérôme Stirnemann, Thierry Levade, Nathalie Andrieu-Abadie, and Frédérique Sabourdy. “Potential Role of Sphingolipidoses-Associated Lysosphingolipids in Cancer.” Cancers 14, no. 19 (October 5, 2022): 4858. https://doi.org/10.3390/cancers14194858.
Carrier, Arnaud, Cécile Desjobert, Loic Ponger, Laurence Lamant, Matias Bustos, Jorge Torres-Ferreira, Rui Henrique, et al. “DNA Methylome Combined with Chromosome Cluster-Oriented Analysis Provides an Early Signature for Cutaneous Melanoma Aggressiveness.” eLife 11 (September 20, 2022): e78587. https://doi.org/10.7554/eLife.78587.
Lazar, Ikrame, Emily Clement, Lorry Carrié, David Esteve, Stéphanie Dauvillier, Mohamed Moutahir, Stéphane Dalle, et al. “Adipocyte Extracellular Vesicles Decrease p16INK4A in Melanoma: An Additional Link between Obesity and Cancer.” The Journal of Investigative Dermatology 142, no. 9 (September 2022): 2488-2498.e8. https://doi.org/10.1016/j.jid.2022.01.026.
Fougerat, Anne, Gabriele Schoiswohl, Arnaud Polizzi, Marion Régnier, Carina Wagner, Sarra Smati, Tiffany Fougeray, et al. “ATGL-Dependent White Adipose Tissue Lipolysis Controls Hepatocyte PPARα Activity.” Cell Reports 39, no. 10 (June 7, 2022): 110910. https://doi.org/10.1016/j.celrep.2022.110910.
Germain, Dominique P., Thierry Levade, Eric Hachulla, Bertrand Knebelmann, Didier Lacombe, Vanessa Leguy Seguin, Karine Nguyen, Esther Noël, and Jean-Pierre Rabès. “Challenging the Traditional Approach for Interpreting Genetic Variants: Lessons from Fabry Disease.” Clinical Genetics 101, no. 4 (April 2022): 390–402. https://doi.org/10.1111/cge.14102.
Dummer, Reinhard, Georgina V. Long, Caroline Robert, Hussein A. Tawbi, Keith T. Flaherty, Paolo A. Ascierto, Paul D. Nathan, et al. “Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, January 14, 2022, JCO2101601. https://doi.org/10.1200/JCO.21.01601.
Pippa, Corrie, Meyer Nicolas, Berardi Rossana, Guidoboni Massimo, Schlueter Maximilian, Kolovos Spyros, Macabeo Bérengère, Trouiller Jean-Baptiste, and Laramée Philippe. “Comparative Efficacy and Safety of Targeted Therapies for BRAF-Mutant Unresectable or Metastatic Melanoma: Results from a Systematic Literature Review and a Network Meta-Analysis.” Cancer Treatment Reviews 110 (2022): 102463. https://doi.org/10.1016/j.ctrv.2022.102463.
PUBLICATIONS 2021
7813506
KC3WFBJR
2021
1
chicago-fullnote-bibliography
50
date
desc
42676
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%229IBDR2N8%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Montfort%20et%20al.%22%2C%22parsedDate%22%3A%222021-09%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMontfort%2C%20Anne%2C%20Mathieu%20Virazels%2C%20C%26%23xE9%3Bline%20Colacios%2C%20Nicolas%20Meyer%2C%20and%20Bruno%20S%26%23xE9%3Bgui.%20%26%23x201C%3BCombining%20TNF%20Blockade%20with%20Immune%20Checkpoint%20Inhibitors%20in%20Patients%20with%20Cancer.%26%23x201D%3B%20%26lt%3Bi%26gt%3BNature%20Reviews.%20Rheumatology%26lt%3B%5C%2Fi%26gt%3B%2017%2C%20no.%209%20%28September%202021%29%3A%20577.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41584-021-00653-8%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41584-021-00653-8%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Combining%20TNF%20blockade%20with%20immune%20checkpoint%20inhibitors%20in%20patients%20with%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Montfort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Virazels%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Colacios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22S%5Cu00e9gui%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222021-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41584-021-00653-8%22%2C%22ISSN%22%3A%221759-4804%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222021-10-29T14%3A22%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22STA4MH4L%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Marcheteau%20et%20al.%22%2C%22parsedDate%22%3A%222021-08-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMarcheteau%2C%20Elie%2C%20Thomas%20Farge%2C%20Micha%26%23xEB%3Bl%20P%26%23xE9%3Br%26%23xE8%3Bs%2C%20Guillaume%20Labrousse%2C%20Julie%20Tenet%2C%20St%26%23xE9%3Bphanie%20Delmas%2C%20Maud%20Chusseau%2C%20et%20al.%20%26%23x201C%3BThrombospondin-1%20Silencing%20Improves%20Lymphocyte%20Infiltration%20in%20Tumors%20and%20Response%20to%20Anti-PD-1%20in%20Triple-Negative%20Breast%20Cancer.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancers%26lt%3B%5C%2Fi%26gt%3B%2013%2C%20no.%2016%20%28August%2012%2C%202021%29%3A%204059.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers13164059%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers13164059%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Thrombospondin-1%20Silencing%20Improves%20Lymphocyte%20Infiltration%20in%20Tumors%20and%20Response%20to%20Anti-PD-1%20in%20Triple-Negative%20Breast%20Cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elie%22%2C%22lastName%22%3A%22Marcheteau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Farge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Micha%5Cu00ebl%22%2C%22lastName%22%3A%22P%5Cu00e9r%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Labrousse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Tenet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Delmas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Chusseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rapha%5Cu00eblle%22%2C%22lastName%22%3A%22Duprez-Paumier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Franchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Dalenc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Imbert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justine%22%2C%22lastName%22%3A%22Noujar%5Cu00e8de%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Colacios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Prats%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Cabon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22S%5Cu00e9gui%22%7D%5D%2C%22abstractNote%22%3A%22Triple-negative%20breast%20cancer%20%28TNBC%29%20is%20notoriously%20aggressive%20with%20a%20high%20metastatic%20potential%2C%20and%20targeted%20therapies%20are%20lacking.%20Using%20transcriptomic%20and%20histologic%20analysis%20of%20TNBC%20samples%2C%20we%20found%20that%20a%20high%20expression%20of%20thrombospondin-1%20%28TSP1%29%2C%20a%20potent%20endogenous%20inhibitor%20of%20angiogenesis%20and%20an%20activator%20of%20latent%20transforming%20growth%20factor%20beta%20%28TGF-%5Cu03b2%29%2C%20is%20associated%20with%20%28i%29%20gene%20signatures%20of%20epithelial-mesenchymal%20transition%20and%20TGF-%5Cu03b2%20signaling%2C%20%28ii%29%20metastasis%20and%20%28iii%29%20a%20reduced%20survival%20in%20TNBC%20patients.%20In%20contrast%2C%20in%20tumors%20expressing%20low%20levels%20of%20TSP1%2C%20gene%20signatures%20of%20interferon%20gamma%20%28IFN-%5Cu03b3%29%20signaling%20and%20lymphocyte%20activation%20were%20enriched.%20In%20TNBC%20biopsies%2C%20TSP1%20expression%20inversely%20correlated%20with%20the%20CD8%2B%20tumor-infiltrating%20lymphocytes%20%28TILs%29%20content.%20In%20the%204T1%20metastatic%20mouse%20model%20of%20TNBC%2C%20TSP1%20silencing%20did%20not%20affect%20primary%20tumor%20development%20but%2C%20strikingly%2C%20impaired%20metastasis%20in%20immunocompetent%20but%20not%20in%20immunodeficient%20nude%20mice.%20Moreover%2C%20TSP1%20knockdown%20increased%20tumor%20vascularization%20and%20T%20lymphocyte%20infiltration%20and%20decreased%20TGF-%5Cu03b2%20activation%20in%20immunocompetent%20mice.%20Noteworthy%20was%20the%20finding%20that%20TSP1%20knockdown%20increased%20CD8%2B%20TILs%20and%20their%20programmed%20cell%20death%201%20%28PD-1%29%20expression%20and%20sensitized%204T1%20tumors%20to%20anti-PD-1%20therapy.%20TSP1%20inhibition%20might%20thus%20represent%20an%20innovative%20targeted%20approach%20to%20impair%20TGF-%5Cu03b2%20activation%20and%20breast%20cancer%20cell%20metastasis%20and%20improve%20lymphocyte%20infiltration%20in%20tumors%2C%20and%20immunotherapy%20efficacy%20in%20TNBC.%22%2C%22date%22%3A%222021-08-12%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers13164059%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222021-10-12T10%3A55%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22KUY9N6L4%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rabiller%20et%20al.%22%2C%22parsedDate%22%3A%222021-08-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BRabiller%2C%20Lise%2C%20Virginie%20Robert%2C%20Ad%26%23xE8%3Ble%20Arlat%2C%20Elodie%20Labit%2C%20Marielle%20Ousset%2C%20Marie%20Salon%2C%20Agn%26%23xE8%3Bs%20Coste%2C%20et%20al.%20%26%23x201C%3BDriving%20Regeneration%2C%20Instead%20of%20Healing%2C%20in%20Adult%20Mammals%3A%20The%20Decisive%20Role%20of%20Resident%20Macrophages%20through%20Efferocytosis.%26%23x201D%3B%20%26lt%3Bi%26gt%3BNPJ%20Regenerative%20Medicine%26lt%3B%5C%2Fi%26gt%3B%206%2C%20no.%201%20%28August%203%2C%202021%29%3A%2041.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41536-021-00151-1%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41536-021-00151-1%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Driving%20regeneration%2C%20instead%20of%20healing%2C%20in%20adult%20mammals%3A%20the%20decisive%20role%20of%20resident%20macrophages%20through%20efferocytosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lise%22%2C%22lastName%22%3A%22Rabiller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ad%5Cu00e8le%22%2C%22lastName%22%3A%22Arlat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Labit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marielle%22%2C%22lastName%22%3A%22Ousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Salon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Coste%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9a%22%2C%22lastName%22%3A%22Da%20Costa-Fernandes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Monsarrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22S%5Cu00e9gui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mireille%22%2C%22lastName%22%3A%22Andr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Guissard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Laure%22%2C%22lastName%22%3A%22Renoud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Mithieux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Raymond-Letron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%22%2C%22lastName%22%3A%22P%5Cu00e9nicaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Lorsignol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Casteilla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Dromard%20Berth%5Cu00e9z%5Cu00e8ne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9atrice%22%2C%22lastName%22%3A%22Cousin%22%7D%5D%2C%22abstractNote%22%3A%22Tissue%20repair%20after%20lesion%20usually%20leads%20to%20scar%20healing%20and%20thus%20loss%20of%20function%20in%20adult%20mammals.%20In%20contrast%2C%20other%20adult%20vertebrates%20such%20as%20amphibians%20have%20the%20ability%20to%20regenerate%20and%20restore%20tissue%20homeostasis%20after%20lesion.%20Understanding%20the%20control%20of%20the%20repair%20outcome%20is%20thus%20a%20concerning%20challenge%20for%20regenerative%20medicine.%20We%20recently%20developed%20a%20model%20of%20induced%20tissue%20regeneration%20in%20adult%20mice%20allowing%20the%20comparison%20of%20the%20early%20steps%20of%20regenerative%20and%20scar%20healing%20processes.%20By%20using%20studies%20of%20gain%20and%20loss%20of%20function%2C%20specific%20cell%20depletion%20approaches%2C%20and%20hematopoietic%20chimeras%20we%20demonstrate%20here%20that%20tissue%20regeneration%20in%20adult%20mammals%20depends%20on%20an%20early%20and%20transient%20peak%20of%20granulocyte%20producing%20reactive%20oxygen%20species%20and%20an%20efficient%20efferocytosis%20specifically%20by%20tissue-resident%20macrophages.%20These%20findings%20highlight%20key%20and%20early%20cellular%20pathways%20able%20to%20drive%20tissue%20repair%20towards%20regeneration%20in%20adult%20mammals.%22%2C%22date%22%3A%222021-08-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41536-021-00151-1%22%2C%22ISSN%22%3A%222057-3995%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222021-10-12T10%3A57%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22M9MWJMJD%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Montfort%20et%20al.%22%2C%22parsedDate%22%3A%222021-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMontfort%2C%20Anne%2C%20Florie%20Bertrand%2C%20Julia%20Rochotte%2C%20Julia%20Gilhodes%2C%20Thomas%20Filleron%2C%20Jean%20Milh%26%23xE8%3Bs%2C%20Carine%20Dufau%2C%20et%20al.%20%26%23x201C%3BNeutral%20Sphingomyelinase%202%20Heightens%20Anti-Melanoma%20Immune%20Responses%20and%20Anti-PD-1%20Therapy%20Efficacy.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancer%20Immunology%20Research%26lt%3B%5C%2Fi%26gt%3B%209%2C%20no.%205%20%28May%202021%29%3A%20568%26%23x2013%3B82.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F2326-6066.CIR-20-0342%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F2326-6066.CIR-20-0342%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Neutral%20Sphingomyelinase%202%20Heightens%20Anti-Melanoma%20Immune%20Responses%20and%20Anti-PD-1%20Therapy%20Efficacy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Montfort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florie%22%2C%22lastName%22%3A%22Bertrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Rochotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Gilhodes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Milh%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Dufau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Imbert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jo%5Cu00eblle%22%2C%22lastName%22%3A%22Riond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Tosolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%20J.%22%2C%22lastName%22%3A%22Clarke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Dufour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrei%20A.%22%2C%22lastName%22%3A%22Constantinescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nilton%20De%20Fran%5Cu00e7a%22%2C%22lastName%22%3A%22Junior%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Record%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Cordelier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Brousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Rochaix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Silvente-Poirot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicole%22%2C%22lastName%22%3A%22Therville%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Andrieu-Abadie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yusuf%20A.%22%2C%22lastName%22%3A%22Hannun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Benoist%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Micheau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Colacios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22S%5Cu00e9gui%22%7D%5D%2C%22abstractNote%22%3A%22Dysregulation%20of%20lipid%20metabolism%20affects%20the%20behavior%20of%20cancer%20cells%2C%20but%20how%20this%20happens%20is%20not%20completely%20understood.%20Neutral%20sphingomyelinase%202%20%28nSMase2%29%2C%20encoded%20by%20SMPD3%2C%20catalyzes%20the%20breakdown%20of%20sphingomyelin%20to%20produce%20the%20anti-oncometabolite%20ceramide.%20We%20found%20that%20this%20enzyme%20was%20often%20downregulated%20in%20human%20metastatic%20melanoma%2C%20likely%20contributing%20to%20immune%20escape.%20Overexpression%20of%20nSMase2%20in%20mouse%20melanoma%20reduced%20tumor%20growth%20in%20syngeneic%20wild-type%20but%20not%20CD8-deficient%20mice.%20In%20wild-type%20mice%2C%20nSMase2-overexpressing%20tumors%20showed%20accumulation%20of%20both%20ceramide%20and%20CD8%2B%20tumor-infiltrating%20lymphocytes%2C%20and%20this%20was%20associated%20with%20increased%20level%20of%20transcripts%20encoding%20IFN%5Cu03b3%20and%20CXCL9.%20Overexpressing%20the%20catalytically%20inactive%20nSMase2%20failed%20to%20alter%20tumor%20growth%2C%20indicating%20that%20the%20deleterious%20effect%20nSMase2%20has%20on%20melanoma%20growth%20depends%20on%20its%20enzymatic%20activity.%20In%20vitro%2C%20small%20extracellular%20vesicles%20from%20melanoma%20cells%20overexpressing%20wild-type%20nSMase2%20augmented%20the%20expression%20of%20IL12%2C%20CXCL9%2C%20and%20CCL19%20by%20bone%20marrow-derived%20dendritic%20cells%2C%20suggesting%20that%20melanoma%20nSMase2%20triggers%20T%20helper%201%20%28Th1%29%20polarization%20in%20the%20earliest%20stages%20of%20the%20immune%20response.%20Most%20importantly%2C%20overexpression%20of%20wild-type%20nSMase2%20increased%20anti-PD-1%20efficacy%20in%20murine%20models%20of%20melanoma%20and%20breast%20cancer%2C%20and%20this%20was%20associated%20with%20an%20enhanced%20Th1%20response.%20Therefore%2C%20increasing%20SMPD3%20expression%20in%20melanoma%20may%20serve%20as%20an%20original%20therapeutic%20strategy%20to%20potentiate%20Th1%20polarization%20and%20CD8%2B%20T-cell-dependent%20immune%20responses%20and%20overcome%20resistance%20to%20anti-PD-1.%22%2C%22date%22%3A%222021-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1158%5C%2F2326-6066.CIR-20-0342%22%2C%22ISSN%22%3A%222326-6074%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226BDVTCJV%22%2C%22S3JJUU84%22%2C%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222021-06-16T13%3A47%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22Z9XA4G7G%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sacher%20et%20al.%22%2C%22parsedDate%22%3A%222021-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSacher%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%2C%20Estelle%20Gandjbakhch%2C%20Philippe%20Maury%2C%20Catherine%20Jenny%2C%20Jonathan%20Khalifa%2C%20Serge%20Boveda%2C%20Pascal%20Defaye%2C%20et%20al.%20%26%23x201C%3BFocus%20on%20Stereotactic%20Radiotherapy%3A%20A%20New%20Way%20to%20Treat%20Severe%20Ventricular%20Arrhythmias%3F%26%23x201D%3B%20%26lt%3Bi%26gt%3BArchives%20of%20Cardiovascular%20Diseases%26lt%3B%5C%2Fi%26gt%3B%20114%2C%20no.%202%20%28February%202021%29%3A%20140%26%23x2013%3B49.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.acvd.2020.11.003%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.acvd.2020.11.003%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Focus%20on%20stereotactic%20radiotherapy%3A%20A%20new%20way%20to%20treat%20severe%20ventricular%20arrhythmias%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Sacher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Estelle%22%2C%22lastName%22%3A%22Gandjbakhch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Maury%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Jenny%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Khalifa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serge%22%2C%22lastName%22%3A%22Boveda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Defaye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Gras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Klug%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Lellouche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Mansourati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eloi%22%2C%22lastName%22%3A%22Marijon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Piot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22Taieb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hubert%22%2C%22lastName%22%3A%22Cochet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Maingon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Pruvot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Fauchier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Working%20Group%20of%20Cardiac%20Pacing%2C%20Electrophysiology%20of%20the%20French%20Society%20of%20Cardiology%22%7D%5D%2C%22abstractNote%22%3A%22Ventricular%20tachycardia%20has%20a%20significant%20recurrence%20rate%20after%20ablation%20for%20several%20reasons%2C%20including%20inaccessible%20substrate.%20A%20non-invasive%20technique%20to%20ablate%20any%20defined%20areas%20of%20myocardium%20involved%20in%20arrhythmogenesis%20would%20be%20a%20potentially%20important%20therapeutic%20improvement%20if%20shown%20to%20be%20safe%20and%20effective.%20Early%20feasibility%20studies%20of%20single-fraction%20stereotactic%20body%20radiotherapy%20have%20demonstrated%20encouraging%20results%2C%20but%20rigorous%20evaluation%20and%20follow-up%20are%20required.%20In%20this%20document%2C%20the%20basic%20concepts%20of%20stereotactic%20body%20radiotherapy%20are%20summarized%2C%20before%20focusing%20on%20stereotactic%20arrhythmia%20radioablation.%20We%20describe%20the%20effect%20of%20radioablation%20on%20cardiac%20tissue%20and%20its%20interaction%20with%20intracardiac%20devices%2C%20depending%20on%20the%20dose.%20The%20different%20clinical%20studies%20on%20ventricular%20tachycardia%20radioablation%20are%20analysed%2C%20with%20a%20focus%20on%20target%20identification%2C%20which%20is%20the%20key%20feature%20of%20this%20approach.%20Our%20document%20ends%20with%20the%20indications%20and%20requirements%20for%20practicing%20this%20type%20of%20procedure%20in%202020.%20Finally%2C%20because%20of%20the%20limited%20number%20of%20patients%20treated%20so%20far%2C%20we%20encourage%20multicentre%20registries%20with%20long-term%20follow-up.%22%2C%22date%22%3A%222021-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.acvd.2020.11.003%22%2C%22ISSN%22%3A%221875-2128%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222021-06-16T12%3A13%3A26Z%22%7D%7D%5D%7D
Montfort, Anne, Mathieu Virazels, Céline Colacios, Nicolas Meyer, and Bruno Ségui. “Combining TNF Blockade with Immune Checkpoint Inhibitors in Patients with Cancer.” Nature Reviews. Rheumatology 17, no. 9 (September 2021): 577. https://doi.org/10.1038/s41584-021-00653-8.
Marcheteau, Elie, Thomas Farge, Michaël Pérès, Guillaume Labrousse, Julie Tenet, Stéphanie Delmas, Maud Chusseau, et al. “Thrombospondin-1 Silencing Improves Lymphocyte Infiltration in Tumors and Response to Anti-PD-1 in Triple-Negative Breast Cancer.” Cancers 13, no. 16 (August 12, 2021): 4059. https://doi.org/10.3390/cancers13164059.
Rabiller, Lise, Virginie Robert, Adèle Arlat, Elodie Labit, Marielle Ousset, Marie Salon, Agnès Coste, et al. “Driving Regeneration, Instead of Healing, in Adult Mammals: The Decisive Role of Resident Macrophages through Efferocytosis.” NPJ Regenerative Medicine 6, no. 1 (August 3, 2021): 41. https://doi.org/10.1038/s41536-021-00151-1.
Montfort, Anne, Florie Bertrand, Julia Rochotte, Julia Gilhodes, Thomas Filleron, Jean Milhès, Carine Dufau, et al. “Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy.” Cancer Immunology Research 9, no. 5 (May 2021): 568–82. https://doi.org/10.1158/2326-6066.CIR-20-0342.
Sacher, Frédéric, Estelle Gandjbakhch, Philippe Maury, Catherine Jenny, Jonathan Khalifa, Serge Boveda, Pascal Defaye, et al. “Focus on Stereotactic Radiotherapy: A New Way to Treat Severe Ventricular Arrhythmias?” Archives of Cardiovascular Diseases 114, no. 2 (February 2021): 140–49. https://doi.org/10.1016/j.acvd.2020.11.003.
PUBLICATIONS 2020
7813506
KC3WFBJR
2020
1
chicago-fullnote-bibliography
50
date
desc
42676
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22UEG3I9S7%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Montfort%20et%20al.%22%2C%22parsedDate%22%3A%222020-12-03%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMontfort%2C%20Anne%2C%20Thomas%20Filleron%2C%20Mathieu%20Virazels%2C%20Carine%20Dufau%2C%20Jean%20Milh%26%23xE8%3Bs%2C%20C%26%23xE9%3Bcile%20Pages%2C%20Pascale%20Olivier%2C%20et%20al.%20%26%23x201C%3BCombining%20Nivolumab%20and%20Ipilimumab%20with%20Infliximab%20or%20Certolizumab%20in%20Patients%20with%20Advanced%20Melanoma%3A%20First%20Results%20of%20a%20Phase%201b%20Clinical%20Trial.%26%23x201D%3B%20%26lt%3Bi%26gt%3BClinical%20Cancer%20Research%26lt%3B%5C%2Fi%26gt%3B%2C%20December%203%2C%202020%2C%20clincanres.3449.2020.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1078-0432.CCR-20-3449%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1078-0432.CCR-20-3449%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Combining%20nivolumab%20and%20ipilimumab%20with%20infliximab%20or%20certolizumab%20in%20patients%20with%20advanced%20melanoma%3A%20first%20results%20of%20a%20phase%201b%20clinical%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Montfort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Virazels%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Dufau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Milh%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Pages%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Olivier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Mounier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Lusque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Brayer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Andrieu-Abadie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Celine%22%2C%22lastName%22%3A%22Colacios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22S%5Cu00e9gui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meyer%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-12-03%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1158%5C%2F1078-0432.CCR-20-3449%22%2C%22ISSN%22%3A%221078-0432%2C%201557-3265%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fclincancerres.aacrjournals.org%5C%2Flookup%5C%2Fdoi%5C%2F10.1158%5C%2F1078-0432.CCR-20-3449%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A22%3A06Z%22%7D%7D%2C%7B%22key%22%3A%22Z6YX46NC%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pellerin%20et%20al.%22%2C%22parsedDate%22%3A%222020-10-27%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPellerin%2C%20Laurence%2C%20Lorry%20Carri%26%23xE9%3B%2C%20Carine%20Dufau%2C%20Laurence%20Nieto%2C%20Bruno%20S%26%23xE9%3Bgui%2C%20Thierry%20Levade%2C%20Jo%26%23xEB%3Blle%20Riond%2C%20and%20Nathalie%20Andrieu-Abadie.%20%26%23x201C%3BLipid%20Metabolic%20Reprogramming%3A%20Role%20in%20Melanoma%20Progression%20and%20Therapeutic%20Perspectives.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancers%26lt%3B%5C%2Fi%26gt%3B%2012%2C%20no.%2011%20%28October%2027%2C%202020%29%3A%203147.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12113147%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12113147%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Lipid%20metabolic%20Reprogramming%3A%20Role%20in%20Melanoma%20Progression%20and%20Therapeutic%20Perspectives%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Pellerin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorry%22%2C%22lastName%22%3A%22Carri%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Dufau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Nieto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22S%5Cu00e9gui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jo%5Cu00eblle%22%2C%22lastName%22%3A%22Riond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Andrieu-Abadie%22%7D%5D%2C%22abstractNote%22%3A%22Metabolic%20reprogramming%20contributes%20to%20the%20pathogenesis%20and%20heterogeneity%20of%20melanoma.%20It%20is%20driven%20both%20by%20oncogenic%20events%20and%20the%20constraints%20imposed%20by%20a%20nutrient-%20and%20oxygen-scarce%20microenvironment.%20Among%20the%20most%20prominent%20metabolic%20reprogramming%20features%20is%20an%20increased%20rate%20of%20lipid%20synthesis.%20Lipids%20serve%20as%20a%20source%20of%20energy%20and%20form%20the%20structural%20foundation%20of%20all%20membranes%2C%20but%20have%20also%20emerged%20as%20mediators%20that%20not%20only%20impact%20classical%20oncogenic%20signaling%20pathways%2C%20but%20also%20contribute%20to%20melanoma%20progression.%20Various%20alterations%20in%20fatty%20acid%20metabolism%20have%20been%20reported%20and%20can%20contribute%20to%20melanoma%20cell%20aggressiveness.%20Elevated%20expression%20of%20the%20key%20lipogenic%20fatty%20acid%20synthase%20is%20associated%20with%20tumor%20cell%20invasion%20and%20poor%20prognosis.%20Fatty%20acid%20uptake%20from%20the%20surrounding%20microenvironment%2C%20fatty%20acid%20%5Cu03b2-oxidation%20and%20storage%20also%20appear%20to%20play%20an%20essential%20role%20in%20tumor%20cell%20migration.%20The%20aim%20of%20this%20review%20is%20%28i%29%20to%20focus%20on%20the%20major%20alterations%20affecting%20lipid%20storage%20organelles%20and%20lipid%20metabolism.%20A%20particular%20attention%20has%20been%20paid%20to%20glycerophospholipids%2C%20sphingolipids%2C%20sterols%20and%20eicosanoids%2C%20%28ii%29%20to%20discuss%20how%20these%20metabolic%20dysregulations%20contribute%20to%20the%20phenotype%20plasticity%20of%20melanoma%20cells%20and%5C%2For%20melanoma%20aggressiveness%2C%20and%20%28iii%29%20to%20highlight%20therapeutic%20approaches%20targeting%20lipid%20metabolism%20that%20could%20be%20applicable%20for%20melanoma%20treatment.%22%2C%22date%22%3A%222020-10-27%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers12113147%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2072-6694%5C%2F12%5C%2F11%5C%2F3147%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22M3M4XCFV%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Carri%5Cu00e9%20et%20al.%22%2C%22parsedDate%22%3A%222020-08-26%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCarri%26%23xE9%3B%2C%20Lorry%2C%20Mathieu%20Virazels%2C%20Carine%20Dufau%2C%20Anne%20Montfort%2C%20Thierry%20Levade%2C%20Bruno%20S%26%23xE9%3Bgui%2C%20and%20Nathalie%20Andrieu-Abadie.%20%26%23x201C%3BNew%20Insights%20into%20the%20Role%20of%20Sphingolipid%20Metabolism%20in%20Melanoma.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCells%26lt%3B%5C%2Fi%26gt%3B%209%2C%20no.%209%20%28August%2026%2C%202020%29%3A%201967.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcells9091967%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcells9091967%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22New%20Insights%20into%20the%20Role%20of%20Sphingolipid%20Metabolism%20in%20Melanoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorry%22%2C%22lastName%22%3A%22Carri%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Virazels%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Dufau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Montfort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22S%5Cu00e9gui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Andrieu-Abadie%22%7D%5D%2C%22abstractNote%22%3A%22Cutaneous%20melanoma%20is%20a%20deadly%20skin%20cancer%20whose%20aggressiveness%20is%20directly%20linked%20to%20its%20metastatic%20potency.%20Despite%20remarkable%20breakthroughs%20in%20term%20of%20treatments%20with%20the%20emergence%20of%20targeted%20therapy%20and%20immunotherapy%2C%20the%20prognosis%20for%20metastatic%20patients%20remains%20uncertain%20mainly%20because%20of%20resistances.%20Better%20understanding%20the%20mechanisms%20responsible%20for%20melanoma%20progression%20is%20therefore%20essential%20to%20uncover%20new%20therapeutic%20targets.%20Interestingly%2C%20the%20sphingolipid%20metabolism%20is%20dysregulated%20in%20melanoma%20and%20is%20associated%20with%20melanoma%20progression%20and%20resistance%20to%20treatment.%20This%20review%20summarises%20the%20impact%20of%20the%20sphingolipid%20metabolism%20on%20melanoma%20from%20the%20initiation%20to%20metastatic%20dissemination%20with%20emphasis%20on%20melanoma%20plasticity%2C%20immune%20responses%20and%20resistance%20to%20treatments.%22%2C%22date%22%3A%222020-08-26%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fcells9091967%22%2C%22ISSN%22%3A%222073-4409%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2073-4409%5C%2F9%5C%2F9%5C%2F1967%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A22%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22VIXB6BUD%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dubot%20et%20al.%22%2C%22parsedDate%22%3A%222020-02-18%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDubot%2C%20Patricia%2C%20Leonardo%20Astudillo%2C%20Nicole%20Therville%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Brique%20Sabourdy%2C%20J%26%23xE9%3Br%26%23xF4%3Bme%20Stirnemann%2C%20Thierry%20Levade%2C%20and%20Nathalie%20Andrieu-Abadie.%20%26%23x201C%3BAre%20Glucosylceramide-Related%20Sphingolipids%20Involved%20in%20the%20Increased%20Risk%20for%20Cancer%20in%20Gaucher%20Disease%20Patients%3F%20Review%20and%20Hypotheses.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancers%26lt%3B%5C%2Fi%26gt%3B%2012%2C%20no.%202%20%28February%2018%2C%202020%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12020475%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12020475%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Are%20Glucosylceramide-Related%20Sphingolipids%20Involved%20in%20the%20Increased%20Risk%20for%20Cancer%20in%20Gaucher%20Disease%20Patients%3F%20Review%20and%20Hypotheses%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Dubot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leonardo%22%2C%22lastName%22%3A%22Astudillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicole%22%2C%22lastName%22%3A%22Therville%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9rique%22%2C%22lastName%22%3A%22Sabourdy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Stirnemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Andrieu-Abadie%22%7D%5D%2C%22abstractNote%22%3A%22The%20roles%20of%20ceramide%20and%20its%20catabolites%2C%20i.e.%2C%20sphingosine%20and%20sphingosine%201-phosphate%2C%20in%20the%20development%20of%20malignancies%20and%20the%20response%20to%20anticancer%20regimens%20have%20been%20extensively%20described.%20Moreover%2C%20an%20abundant%20literature%20points%20to%20the%20effects%20of%20glucosylceramide%20synthase%2C%20the%20mammalian%20enzyme%20that%20converts%20ceramide%20to%20%5Cu03b2-glucosylceramide%2C%20in%20protecting%20tumor%20cells%20from%20chemotherapy.%20Much%20less%20is%20known%20about%20the%20contribution%20of%20%5Cu03b2-glucosylceramide%20and%20its%20breakdown%20products%20in%20cancer%20progression.%20In%20this%20chapter%2C%20we%20first%20review%20published%20and%20personal%20clinical%20observations%20that%20report%20on%20the%20increased%20risk%20of%20developing%20cancers%20in%20patients%20affected%20with%20Gaucher%20disease%2C%20an%20inborn%20disorder%20characterized%20by%20defective%20lysosomal%20degradation%20of%20%5Cu03b2-glucosylceramide.%20The%20previously%20described%20mechanistic%20links%20between%20lysosomal%20%5Cu03b2-glucosylceramidase%2C%20%5Cu03b2-glucosylceramide%20and%5C%2For%20%5Cu03b2-glucosylphingosine%2C%20and%20various%20hallmarks%20of%20cancer%20are%20reviewed.%20We%20further%20show%20that%20melanoma%20tumor%20growth%20is%20facilitated%20in%20a%20Gaucher%20disease%20mouse%20model.%20Finally%2C%20the%20potential%20roles%20of%20the%20%5Cu03b2-glucosylceramidase%20protein%20and%20its%20lipidic%20substrates%20and%5C%2For%20downstream%20products%20are%20discussed.%22%2C%22date%22%3A%22Feb%2018%2C%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers12020475%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A28Z%22%7D%7D%2C%7B%22key%22%3A%22AVZR84G4%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Imbert%20et%20al.%22%2C%22parsedDate%22%3A%222020-01-23%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BImbert%2C%20Caroline%2C%20Anne%20Montfort%2C%20Marine%20Fraisse%2C%20Elie%20Marcheteau%2C%20Julia%20Gilhodes%2C%20Elodie%20Martin%2C%20Florie%20Bertrand%2C%20et%20al.%20%26%23x201C%3BResistance%20of%20Melanoma%20to%20Immune%20Checkpoint%20Inhibitors%20Is%20Overcome%20by%20Targeting%20the%20Sphingosine%20Kinase-1.%26%23x201D%3B%20%26lt%3Bi%26gt%3BNature%20Communications%26lt%3B%5C%2Fi%26gt%3B%2011%2C%20no.%201%20%28January%2023%2C%202020%29%3A%20437.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41467-019-14218-7%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41467-019-14218-7%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Resistance%20of%20melanoma%20to%20immune%20checkpoint%20inhibitors%20is%20overcome%20by%20targeting%20the%20sphingosine%20kinase-1%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Imbert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Montfort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Fraisse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elie%22%2C%22lastName%22%3A%22Marcheteau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Gilhodes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florie%22%2C%22lastName%22%3A%22Bertrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marl%5Cu00e8ne%22%2C%22lastName%22%3A%22Marcellin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Odile%22%2C%22lastName%22%3A%22Burlet-Schiltz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%20Gonzalez%20de%22%2C%22lastName%22%3A%22Peredo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Carpentier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Tartare-Deckert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Brousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Rochaix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Puisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Lamant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22S%5Cu00e9gui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Andrieu-Abadie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Colacios%22%7D%5D%2C%22abstractNote%22%3A%22Immune%20checkpoint%20inhibitors%20%28ICIs%29%20have%20dramatically%20modified%20the%20prognosis%20of%20several%20advanced%20cancers%2C%20however%20many%20patients%20still%20do%20not%20respond%20to%20treatment.%20Optimal%20results%20might%20be%20obtained%20by%20targeting%20cancer%20cell%20metabolism%20to%20modulate%20the%20immunosuppressive%20tumor%20microenvironment.%20Here%2C%20we%20identify%20sphingosine%20kinase-1%20%28SK1%29%20as%20a%20key%20regulator%20of%20anti-tumor%20immunity.%20Increased%20expression%20of%20SK1%20in%20tumor%20cells%20is%20significantly%20associated%20with%20shorter%20survival%20in%20metastatic%20melanoma%20patients%20treated%20with%20anti-PD-1.%20Targeting%20SK1%20markedly%20enhances%20the%20responses%20to%20ICI%20in%20murine%20models%20of%20melanoma%2C%20breast%20and%20colon%20cancer.%20Mechanistically%2C%20SK1%20silencing%20decreases%20the%20expression%20of%20various%20immunosuppressive%20factors%20in%20the%20tumor%20microenvironment%20to%20limit%20regulatory%20T%20cell%20%28Treg%29%20infiltration.%20Accordingly%2C%20a%20SK1-dependent%20immunosuppressive%20signature%20is%20also%20observed%20in%20human%20melanoma%20biopsies.%20Altogether%2C%20this%20study%20identifies%20SK1%20as%20a%20checkpoint%20lipid%20kinase%20that%20could%20be%20targeted%20to%20enhance%20immunotherapy.%22%2C%22date%22%3A%22Jan%2023%2C%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41467-019-14218-7%22%2C%22ISSN%22%3A%222041-1723%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A08Z%22%7D%7D%5D%7D
Montfort, Anne, Thomas Filleron, Mathieu Virazels, Carine Dufau, Jean Milhès, Cécile Pages, Pascale Olivier, et al. “Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase 1b Clinical Trial.” Clinical Cancer Research, December 3, 2020, clincanres.3449.2020. https://doi.org/10.1158/1078-0432.CCR-20-3449.
Pellerin, Laurence, Lorry Carrié, Carine Dufau, Laurence Nieto, Bruno Ségui, Thierry Levade, Joëlle Riond, and Nathalie Andrieu-Abadie. “Lipid Metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives.” Cancers 12, no. 11 (October 27, 2020): 3147. https://doi.org/10.3390/cancers12113147.
Carrié, Lorry, Mathieu Virazels, Carine Dufau, Anne Montfort, Thierry Levade, Bruno Ségui, and Nathalie Andrieu-Abadie. “New Insights into the Role of Sphingolipid Metabolism in Melanoma.” Cells 9, no. 9 (August 26, 2020): 1967. https://doi.org/10.3390/cells9091967.
Dubot, Patricia, Leonardo Astudillo, Nicole Therville, Frédérique Sabourdy, Jérôme Stirnemann, Thierry Levade, and Nathalie Andrieu-Abadie. “Are Glucosylceramide-Related Sphingolipids Involved in the Increased Risk for Cancer in Gaucher Disease Patients? Review and Hypotheses.” Cancers 12, no. 2 (February 18, 2020). https://doi.org/10.3390/cancers12020475.
Imbert, Caroline, Anne Montfort, Marine Fraisse, Elie Marcheteau, Julia Gilhodes, Elodie Martin, Florie Bertrand, et al. “Resistance of Melanoma to Immune Checkpoint Inhibitors Is Overcome by Targeting the Sphingosine Kinase-1.” Nature Communications 11, no. 1 (January 23, 2020): 437. https://doi.org/10.1038/s41467-019-14218-7.
PUBLICATIONS 2019
7813506
KC3WFBJR
2019
1
chicago-fullnote-bibliography
50
date
desc
42676
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22N2Y6QVUW%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Montfort%20et%20al.%22%2C%22parsedDate%22%3A%222019-11-14%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMontfort%2C%20Anne%2C%20Carine%20Dufau%2C%20C%26%23xE9%3Bline%20Colacios%2C%20Nathalie%20Andrieu-Abadie%2C%20Thierry%20Levade%2C%20Thomas%20Filleron%2C%20Jean-Pierre%20Delord%2C%20Maha%20Ayyoub%2C%20Nicolas%20Meyer%2C%20and%20Bruno%20S%26%23xE9%3Bgui.%20%26%23x201C%3BAnti-TNF%2C%20a%20Magic%20Bullet%20in%20Cancer%20Immunotherapy%3F%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20for%20Immunotherapy%20of%20Cancer%26lt%3B%5C%2Fi%26gt%3B%207%2C%20no.%201%20%28November%2014%2C%202019%29%3A%20303.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40425-019-0802-y%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40425-019-0802-y%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Anti-TNF%2C%20a%20magic%20bullet%20in%20cancer%20immunotherapy%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Montfort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Dufau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Colacios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Andrieu-Abadie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Delord%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Ayyoub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22S%5Cu00e9gui%22%7D%5D%2C%22abstractNote%22%3A%22Immune%20checkpoint%20blockers%20%28ICB%29%20have%20revolutionized%20cancer%20therapy.%20However%2C%20complete%20response%20is%20observed%20in%20a%20minority%20of%20patients%20and%20most%20patients%20develop%20immune-related%20adverse%20events%20%28irAEs%29.%20These%20include%20colitis%2C%20which%20can%20be%20treated%20with%20anti-tumor%20necrosis%20factor%20%28TNF%29%20antibodies%20such%20as%20Infliximab.%20In%20a%20recent%20issue%20of%20the%20Journal%20for%20ImmunoTherapy%20of%20Cancer%2C%20Badran%20et%20al.%20reported%20that%20co-administering%20Infliximab%20together%20with%20ICB%20to%20five%20cancer%20patients%20prevents%20colitis%20recurrence%2C%20with%20four%20of%20them%20exhibiting%20overall%20disease%20stability.%20The%20basis%20for%20this%20treatment%20strategy%20stemmed%20from%20our%20pre-clinical%20demonstration%20that%20TNF%20contributes%20to%20resistance%20to%20anti-PD-1%20therapy.%20In%20agreement%20with%20this%20concept%2C%20we%20have%20shown%20that%20TNF%20blockers%20improve%20the%20anti-tumor%20therapeutic%20activity%20of%20ICB%20in%20mice%20and%20based%20on%20these%20findings%20we%20are%20currently%20evaluating%20the%20combination%20in%20melanoma%20patients%20enrolled%20in%20the%20TICIMEL%20clinical%20trial.%20Herein%2C%20%28i%29%20we%20discuss%20the%20scientific%20rationale%20for%20combining%20anti-TNF%20and%20ICB%20in%20cancer%20patients%2C%20%28ii%29%20comment%20on%20the%20paper%20published%20by%20Badran%20et%20al.%20and%20%28iii%29%20provide%20the%20TICIMEL%20clinical%20trial%20design.%22%2C%22date%22%3A%22Nov%2014%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs40425-019-0802-y%22%2C%22ISSN%22%3A%222051-1426%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A45Z%22%7D%7D%2C%7B%22key%22%3A%226R9NNCL6%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dubot%20et%20al.%22%2C%22parsedDate%22%3A%222019-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDubot%2C%20Patricia%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Brique%20Sabourdy%2C%20Jitka%20Rybova%2C%20Jeffrey%20A.%20Medin%2C%20and%20Thierry%20Levade.%20%26%23x201C%3BInherited%20Monogenic%20Defects%20of%20Ceramide%20Metabolism%3A%20Molecular%20Bases%20and%20Diagnoses.%26%23x201D%3B%20%26lt%3Bi%26gt%3BClinica%20Chimica%20Acta%3B%20International%20Journal%20of%20Clinical%20Chemistry%26lt%3B%5C%2Fi%26gt%3B%20495%20%28August%202019%29%3A%20457%26%23x2013%3B66.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cca.2019.05.020%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cca.2019.05.020%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Inherited%20monogenic%20defects%20of%20ceramide%20metabolism%3A%20Molecular%20bases%20and%20diagnoses%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Dubot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9rique%22%2C%22lastName%22%3A%22Sabourdy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jitka%22%2C%22lastName%22%3A%22Rybova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeffrey%20A.%22%2C%22lastName%22%3A%22Medin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%5D%2C%22abstractNote%22%3A%22Ceramides%20are%20membrane%20lipids%20implicated%20in%20the%20regulation%20of%20numerous%20biological%20functions.%20Recent%20evidence%20suggests%20that%20specific%20subsets%20of%20molecular%20species%20of%20ceramide%20may%20play%20distinct%20physiological%20roles.%20The%20importance%20of%20this%20family%20of%20molecules%20in%20vertebrates%20is%20witnessed%20by%20the%20deleterious%20consequences%20of%20genetic%20alterations%20in%20ceramide%20metabolism.%20This%20brief%20review%20summarizes%20the%20clinical%20presentation%20of%20human%20disorders%20due%20to%20the%20deficiency%20of%20enzymes%20involved%20either%20in%20the%20biosynthesis%20or%20the%20degradation%20of%20ceramides.%20Information%20on%20the%20possible%20underlying%20pathophysiological%20mechanisms%20is%20also%20provided%2C%20based%20on%20knowledge%20gathered%20from%20animal%20models%20of%20these%20inherited%20rare%20conditions.%20When%20appropriate%2C%20tools%20for%20chemical%20and%20molecular%20diagnosis%20of%20these%20disorders%20and%20therapeutic%20options%20are%20also%20presented.%22%2C%22date%22%3A%222019-08%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.cca.2019.05.020%22%2C%22ISSN%22%3A%221873-3492%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222024-02-13T10%3A17%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22NGF53V5V%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Baudoin-Dehoux%20et%20al.%22%2C%22parsedDate%22%3A%222019-01-19%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBaudoin-Dehoux%2C%20C%26%23xE9%3Bcile%2C%20Tessa%20Castellan%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Rodriguez%2C%20Arnaud%20Rives%2C%20Fabien%20Stauffert%2C%20Virginie%20Garcia%2C%20Thierry%20Levade%2C%20Philippe%20Compain%2C%20and%20Yves%20G%26%23xE9%3Bnisson.%20%26%23x201C%3BSelective%20Targeting%20of%20the%20Interconversion%20between%20Glucosylceramide%20and%20Ceramide%20by%20Scaffold%20Tailoring%20of%20Iminosugar%20Inhibitors.%26%23x201D%3B%20%26lt%3Bi%26gt%3BMolecules%20%28Basel%2C%20Switzerland%29%26lt%3B%5C%2Fi%26gt%3B%2024%2C%20no.%202%20%28January%2019%2C%202019%29%3A%20354.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fmolecules24020354%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fmolecules24020354%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Selective%20Targeting%20of%20the%20Interconversion%20between%20Glucosylceramide%20and%20Ceramide%20by%20Scaffold%20Tailoring%20of%20Iminosugar%20Inhibitors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Baudoin-Dehoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tessa%22%2C%22lastName%22%3A%22Castellan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Rodriguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Rives%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Stauffert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Compain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22G%5Cu00e9nisson%22%7D%5D%2C%22abstractNote%22%3A%22A%20series%20of%20simple%20C-alkyl%20pyrrolidines%20already%20known%20as%20cytotoxic%20inhibitors%20of%20ceramide%20glucosylation%20in%20melanoma%20cells%20can%20be%20converted%20into%20their%20corresponding%206-membered%20analogues%20by%20means%20of%20a%20simple%20ring%20expansion.%20This%20study%20illustrated%20how%20an%20isomerisation%20from%20iminosugar%20pyrrolidine%20toward%20piperidine%20could%20invert%20their%20targeting%20from%20glucosylceramide%20%28GlcCer%29%20formation%20toward%20GlcCer%20hydrolysis.%20Thus%2C%20we%20found%20that%20the%205-membered%20ring%20derivatives%20did%20not%20inhibit%20the%20hydrolysis%20reaction%20of%20GlcCer%20catalysed%20by%20lysosomal%20%5Cu03b2-glucocerebrosidase%20%28GBA%29.%20On%20the%20other%20hand%2C%20the%20ring-expanded%20C-alkyl%20piperidine%20isomers%2C%20non-cytotoxic%20and%20inactive%20regarding%20ceramide%20glucosylation%2C%20revealed%20to%20be%20potent%20inhibitors%20of%20GBA.%20A%20molecular%20docking%20study%20showed%20that%20the%20positions%20of%20the%20piperidine%20ring%20of%20the%20compound%206b%20and%20its%20analogous%202-O-heptyl%20DIX%208%20were%20similar%20to%20that%20of%20isofagomine.%20Furthermore%2C%20compound%206b%20promoted%20mutant%20GBA%20enhancements%20over%203-fold%20equivalent%20to%20that%20of%20the%20related%20O-Hept%20DIX%208%20belonging%20to%20one%20of%20the%20most%20potent%20iminosugar-based%20pharmacological%20chaperone%20series%20reported%20to%20date.%22%2C%22date%22%3A%222019-01-19%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fmolecules24020354%22%2C%22ISSN%22%3A%221420-3049%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222024-02-13T10%3A16%3A49Z%22%7D%7D%2C%7B%22key%22%3A%223946RSUE%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Alaeddine%20et%20al.%22%2C%22parsedDate%22%3A%222019-01-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAlaeddine%2C%20Mohamad%2C%20M%26%23xE9%3Blissa%20Prat%2C%20V%26%23xE9%3Br%26%23xE9%3Bna%20Hauke%20Poinsot%2C%20Val%26%23xE9%3Brie%20Gouaz%26%23xE9%3B-Andersson%2C%20H%26%23xE9%3Bl%26%23xE8%3Bne%20Authier%2C%20Etienne%20Meunier%2C%20Lise%20Lef%26%23xE8%3Bvre%2C%20et%20al.%20%26%23x201C%3BIL13-Mediated%20Dectin-1%20and%20Mannose%20Receptor%20Overexpression%20Promotes%20Macrophage%20Antitumor%20Activities%20through%20Recognition%20of%20Sialylated%20Tumor%20Cells.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancer%20Immunology%20Research%26lt%3B%5C%2Fi%26gt%3B%2C%20January%204%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F2326-6066.CIR-18-0213%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F2326-6066.CIR-18-0213%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22IL13-mediated%20dectin-1%20and%20mannose%20receptor%20overexpression%20promotes%20macrophage%20antitumor%20activities%20through%20recognition%20of%20sialylated%20tumor%20cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohamad%22%2C%22lastName%22%3A%22Alaeddine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lissa%22%2C%22lastName%22%3A%22Prat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9r%5Cu00e9na%20Hauke%22%2C%22lastName%22%3A%22Poinsot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Gouaz%5Cu00e9-Andersson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Authier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Meunier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lise%22%2C%22lastName%22%3A%22Lef%5Cu00e8vre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Alric%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Dardenne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%22%2C%22lastName%22%3A%22Bernad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Alric%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22S%5Cu00e9gui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Balard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Couderc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bettina%22%2C%22lastName%22%3A%22Couderc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Pipy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Coste%22%7D%5D%2C%22abstractNote%22%3A%22Macrophage-mediated%20cytotoxicity%20is%20controlled%20by%20surface%20receptor%20expression%20and%20activation.%20Despite%20the%20numerous%20studies%20documenting%20the%20role%20of%20macrophage%20C-type%20lectin%20receptors%20%28CLRs%29%20in%20pathogen%20elimination%2C%20little%20is%20known%20about%20their%20contribution%20to%20antitumor%20responses.%20Here%2C%20we%20report%20that%20IL13%20inhibits%20T-cell%20lymphoma%20and%20ovarian%20adenocarcinoma%20development%20in%20tumor-bearing%20mice%20through%20the%20conversion%20of%20tumor-supporting%20macrophages%20to%20cytotoxic%20effectors%2C%20characterized%20by%20a%20CLR%20signature%20composed%20of%20dectin-1%20and%20mannose%20receptor%20%28MR%29.%20We%20show%20that%20dectin-1%20and%20MR%20are%20critical%20for%20the%20recognition%20of%20tumor%20cells%20through%20sialic%20acid-specific%20glycan%20structure%20on%20their%20surface%20and%20for%20the%20subsequent%20activation%20of%20macrophage%20tumoricidal%20response.%20Finally%2C%20we%20validated%20that%20IL13%20antitumor%20effect%20mediated%20by%20dectin-1%20and%20MR%20overexpression%20on%20macrophages%20can%20extend%20to%20various%20types%20of%20human%20tumors.%20Therefore%2C%20these%20results%20identify%20these%20CLRs%20as%20potential%20targets%20to%20promote%20macrophage%20antitumor%20response%20and%20represent%20an%20attractive%20approach%20to%20elicit%20tumor-associated%20macrophage%20tumoricidal%20properties.%22%2C%22date%22%3A%22Jan%2004%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1158%5C%2F2326-6066.CIR-18-0213%22%2C%22ISSN%22%3A%222326-6074%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A22%3A55Z%22%7D%7D%2C%7B%22key%22%3A%229ILAKLAL%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Leclerc%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLeclerc%2C%20Justine%2C%20David%20Garandeau%2C%20Charlotte%20Pandiani%2C%20C%26%23xE9%3Bline%20Gaudel%2C%20Karine%20Bille%2C%20Nicolas%20Nottet%2C%20Virginie%20Garcia%2C%20et%20al.%20%26%23x201C%3BLysosomal%20Acid%20Ceramidase%20ASAH1%20Controls%20the%20Transition%20between%20Invasive%20and%20Proliferative%20Phenotype%20in%20Melanoma%20Cells.%26%23x201D%3B%20%26lt%3Bi%26gt%3BOncogene%26lt%3B%5C%2Fi%26gt%3B%2038%2C%20no.%208%20%282019%29%3A%201282%26%23x2013%3B95.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41388-018-0500-0%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41388-018-0500-0%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Lysosomal%20acid%20ceramidase%20ASAH1%20controls%20the%20transition%20between%20invasive%20and%20proliferative%20phenotype%20in%20melanoma%20cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justine%22%2C%22lastName%22%3A%22Leclerc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Garandeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Pandiani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Gaudel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karine%22%2C%22lastName%22%3A%22Bille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Nottet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Colosetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Pagnotta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Bahadoran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Garance%22%2C%22lastName%22%3A%22Tondeur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Baharia%22%2C%22lastName%22%3A%22Mograbi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Dalle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Caramel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Ballotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Andrieu-Abadie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corine%22%2C%22lastName%22%3A%22Bertolotto%22%7D%5D%2C%22abstractNote%22%3A%22Phenotypic%20plasticity%20and%20subsequent%20generation%20of%20intratumoral%20heterogeneity%20underly%20key%20traits%20in%20malignant%20melanoma%20such%20as%20drug%20resistance%20and%20metastasis.%20Melanoma%20plasticity%20promotes%20a%20switch%20between%20proliferative%20and%20invasive%20phenotypes%20characterized%20by%20different%20transcriptional%20programs%20of%20which%20MITF%20is%20a%20critical%20regulator.%20Here%2C%20we%20show%20that%20the%20acid%20ceramidase%20ASAH1%2C%20which%20controls%20sphingolipid%20metabolism%2C%20acted%20as%20a%20rheostat%20of%20the%20phenotypic%20switch%20in%20melanoma%20cells.%20Low%20ASAH1%20expression%20was%20associated%20with%20an%20invasive%20behavior%20mediated%20by%20activation%20of%20the%20integrin%20alphavbeta5-FAK%20signaling%20cascade.%20In%20line%20with%20that%2C%20human%20melanoma%20biopsies%20revealed%20heterogeneous%20staining%20of%20ASAH1%20and%20low%20ASAH1%20expression%20at%20the%20melanoma%20invasive%20front.%20We%20also%20identified%20ASAH1%20as%20a%20new%20target%20of%20MITF%2C%20thereby%20involving%20MITF%20in%20the%20regulation%20of%20sphingolipid%20metabolism.%20Together%2C%20our%20findings%20provide%20new%20cues%20to%20the%20mechanisms%20underlying%20the%20phenotypic%20plasticity%20of%20melanoma%20cells%20and%20identify%20new%20anti-metastatic%20targets.%22%2C%22date%22%3A%2202%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41388-018-0500-0%22%2C%22ISSN%22%3A%221476-5594%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222021-10-11T11%3A43%3A38Z%22%7D%7D%2C%7B%22key%22%3A%22W2ZSTAEP%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Garandeau%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGarandeau%2C%20David%2C%20Justine%20Noujar%26%23xE8%3Bde%2C%20Justine%20Leclerc%2C%20Caroline%20Imbert%2C%20Virginie%20Garcia%2C%20Marie-Lise%20Bats%2C%20Florian%20Rambow%2C%20et%20al.%20%26%23x201C%3BTargeting%20the%20Sphingosine%201-Phosphate%20Axis%20Exerts%20Potent%20Antitumor%20Activity%20in%20BRAFi-Resistant%20Melanomas.%26%23x201D%3B%20%26lt%3Bi%26gt%3BMolecular%20Cancer%20Therapeutics%26lt%3B%5C%2Fi%26gt%3B%2018%2C%20no.%202%20%282019%29%3A%20289%26%23x2013%3B300.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1535-7163.MCT-17-1141%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1535-7163.MCT-17-1141%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Targeting%20the%20Sphingosine%201-Phosphate%20Axis%20Exerts%20Potent%20Antitumor%20Activity%20in%20BRAFi-Resistant%20Melanomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Garandeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justine%22%2C%22lastName%22%3A%22Noujar%5Cu00e8de%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justine%22%2C%22lastName%22%3A%22Leclerc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Imbert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Lise%22%2C%22lastName%22%3A%22Bats%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%22%2C%22lastName%22%3A%22Rambow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Gilhodes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Brayer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Silvia%22%2C%22lastName%22%3A%22Arcucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Tartare-Deckert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22S%5Cu00e9gui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Christophe%22%2C%22lastName%22%3A%22Marine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corine%22%2C%22lastName%22%3A%22Bertolotto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Andrieu-Abadie%22%7D%5D%2C%22abstractNote%22%3A%22BRAF%20inhibitors%20%28BRAFi%29%20are%20used%20to%20treat%20patients%20with%20melanoma%20harboring%20the%20V600E%20mutation.%20However%2C%20resistance%20to%20BRAFi%20is%20inevitable.%20Here%2C%20we%20identified%20sphingosine%201-phosphate%20%28S1P%29%20receptors%20as%20regulators%20of%20BRAFV600E-mutant%20melanoma%20cell-autonomous%20resistance%20to%20BRAFi.%20Moreover%2C%20our%20results%20reveal%20a%20distinct%20sphingolipid%20profile%2C%20that%20is%2C%20a%20tendency%20for%20increased%20very%20long-chain%20ceramide%20species%2C%20in%20the%20plasma%20of%20patients%20with%20melanoma%20who%20achieve%20a%20response%20to%20BRAFi%20therapy%20as%20compared%20with%20patients%20with%20progressive%20disease.%20Treatment%20with%20BRAFi%20resulted%20in%20a%20strong%20decrease%20in%20S1PR1%5C%2F3%20expression%20in%20sensitive%20but%20not%20in%20resistant%20cells.%20Genetic%20and%20pharmacologic%20interventions%2C%20that%20increase%20ceramide%5C%2FS1P%20ratio%2C%20downregulated%20S1PR%20expression%20and%20blocked%20BRAFi-resistant%20melanoma%20cell%20growth.%20This%20effect%20was%20associated%20with%20a%20decreased%20expression%20of%20MITF%20and%20Bcl-2.%20Moreover%2C%20the%20BH3%20mimetic%20ABT-737%20improved%20the%20antitumor%20activity%20of%20approaches%20targeting%20S1P-metabolizing%20enzymes%20in%20BRAFi-resistant%20melanoma%20cells.%20Collectively%2C%20our%20findings%20indicate%20that%20targeting%20the%20S1P%5C%2FS1PR%20axis%20could%20provide%20effective%20therapeutic%20options%20for%20patients%20with%20melanoma%20who%20relapse%20after%20BRAFi%20therapy.%22%2C%22date%22%3A%2202%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1158%5C%2F1535-7163.MCT-17-1141%22%2C%22ISSN%22%3A%221538-8514%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222021-07-22T11%3A26%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22AKKIDV95%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Montfort%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMontfort%2C%20Anne%2C%20C%26%23xE9%3Bline%20Colacios%2C%20Thierry%20Levade%2C%20Nathalie%20Andrieu-Abadie%2C%20Nicolas%20Meyer%2C%20and%20Bruno%20S%26%23xE9%3Bgui.%20%26%23x201C%3BCorrigendum%3A%20The%20TNF%20Paradox%20in%20Cancer%20Progression%20and%20Immunotherapy.%26%23x201D%3B%20%26lt%3Bi%26gt%3BFrontiers%20in%20Immunology%26lt%3B%5C%2Fi%26gt%3B%2010%20%282019%29%3A%202515.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2019.02515%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2019.02515%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Corrigendum%3A%20The%20TNF%20Paradox%20in%20Cancer%20Progression%20and%20Immunotherapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Montfort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Colacios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Andrieu-Abadie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22S%5Cu00e9gui%22%7D%5D%2C%22abstractNote%22%3A%22%5BThis%20corrects%20the%20article%20DOI%3A%2010.3389%5C%2Ffimmu.2019.01818.%5D.%22%2C%22date%22%3A%222019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3389%5C%2Ffimmu.2019.02515%22%2C%22ISSN%22%3A%221664-3224%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22X2EIDFAN%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Montfort%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMontfort%2C%20Anne%2C%20C%26%23xE9%3Bline%20Colacios%2C%20Thierry%20Levade%2C%20Nathalie%20Andrieu-Abadie%2C%20Nicolas%20Meyer%2C%20and%20Bruno%20S%26%23xE9%3Bgui.%20%26%23x201C%3BThe%20TNF%20Paradox%20in%20Cancer%20Progression%20and%20Immunotherapy.%26%23x201D%3B%20%26lt%3Bi%26gt%3BFrontiers%20in%20Immunology%26lt%3B%5C%2Fi%26gt%3B%2010%20%282019%29%3A%201818.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2019.01818%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2019.01818%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20TNF%20Paradox%20in%20Cancer%20Progression%20and%20Immunotherapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Montfort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Colacios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Andrieu-Abadie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22S%5Cu00e9gui%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3389%5C%2Ffimmu.2019.01818%22%2C%22ISSN%22%3A%221664-3224%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A33Z%22%7D%7D%2C%7B%22key%22%3A%22EGTGL7L9%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bilal%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBilal%2C%20Fatima%2C%20Anne%20Montfort%2C%20Julia%20Gilhodes%2C%20Virginie%20Garcia%2C%20Jo%26%23xEB%3Blle%20Riond%2C%20St%26%23xE9%3Bphane%20Carpentier%2C%20Thomas%20Filleron%2C%20et%20al.%20%26%23x201C%3BSphingomyelin%20Synthase%201%20%28SMS1%29%20Downregulation%20Is%20Associated%20With%20Sphingolipid%20Reprogramming%20and%20a%20Worse%20Prognosis%20in%20Melanoma.%26%23x201D%3B%20%26lt%3Bi%26gt%3BFrontiers%20in%20Pharmacology%26lt%3B%5C%2Fi%26gt%3B%2010%20%282019%29%3A%20443.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffphar.2019.00443%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffphar.2019.00443%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Sphingomyelin%20Synthase%201%20%28SMS1%29%20Downregulation%20Is%20Associated%20With%20Sphingolipid%20Reprogramming%20and%20a%20Worse%20Prognosis%20in%20Melanoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fatima%22%2C%22lastName%22%3A%22Bilal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Montfort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Gilhodes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jo%5Cu00eblle%22%2C%22lastName%22%3A%22Riond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Carpentier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Colacios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Levade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmad%22%2C%22lastName%22%3A%22Daher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Andrieu-Abadie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22S%5Cu00e9gui%22%7D%5D%2C%22abstractNote%22%3A%22Sphingolipid%20%28SL%29%20metabolism%20alterations%20have%20been%20frequently%20reported%20in%20cancer%20including%20in%20melanoma%2C%20a%20bad-prognosis%20skin%20cancer.%20In%20normal%20cells%2C%20de%20novo%20synthesized%20ceramide%20is%20mainly%20converted%20to%20sphingomyelin%20%28SM%29%2C%20the%20most%20abundant%20SL%2C%20by%20sphingomyelin%20synthase%201%20%28SMS1%29%20and%2C%20albeit%20to%20a%20lesser%20extent%2C%20SMS2%2C%20encoded%20by%20the%20SGMS1%20and%20SGMS2%20genes%2C%20respectively.%20Alternatively%2C%20ceramide%20can%20be%20converted%20to%20glucosylceramide%20%28GlcCer%29%20by%20the%20GlcCer%20synthase%20%28GCS%29%2C%20encoded%20by%20the%20UGCG%20gene.%20Herein%2C%20we%20provide%20evidence%20for%20the%20first%20time%20that%20SMS1%20is%20frequently%20downregulated%20in%20various%20solid%20cancers%2C%20more%20particularly%20in%20melanoma.%20Accordingly%2C%20various%20human%20melanoma%20cells%20displayed%20a%20SL%20metabolism%20signature%20associated%20with%20%28i%29%20a%20robust%20and%20a%20low%20expression%20of%20UGCG%20and%20SGMS1%5C%2F2%2C%20respectively%2C%20%28ii%29%20higher%20in%20situ%20enzyme%20activity%20of%20GCS%20than%20SMS%2C%20and%20%28iii%29%20higher%20intracellular%20levels%20of%20GlcCer%20than%20SM.%20SMS1%20was%20expressed%20at%20low%20levels%20in%20most%20of%20the%20human%20melanoma%20biopsies.%20In%20addition%2C%20several%20mutations%20and%20increased%20CpG%20island%20methylation%20in%20the%20SGMS1%20gene%20were%20identified%20that%20likely%20affect%20SMS1%20expression.%20Finally%2C%20low%20SMS1%20expression%20was%20associated%20with%20a%20worse%20prognosis%20in%20metastatic%20melanoma%20patients.%20Collectively%2C%20our%20study%20indicates%20that%20SMS1%20downregulation%20in%20melanoma%20enhances%20GlcCer%20synthesis%2C%20triggering%20an%20imbalance%20in%20the%20SM%5C%2FGlcCer%20homeostasis%2C%20which%20likely%20contributes%20to%20melanoma%20progression.%20Evaluating%20SMS1%20expression%20level%20in%20tumor%20samples%20might%20serve%20as%20a%20biomarker%20to%20predict%20clinical%20outcome%20in%20advanced%20melanoma%20patients.%22%2C%22date%22%3A%222019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3389%5C%2Ffphar.2019.00443%22%2C%22ISSN%22%3A%221663-9812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KC3WFBJR%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A17Z%22%7D%7D%5D%7D
Montfort, Anne, Carine Dufau, Céline Colacios, Nathalie Andrieu-Abadie, Thierry Levade, Thomas Filleron, Jean-Pierre Delord, Maha Ayyoub, Nicolas Meyer, and Bruno Ségui. “Anti-TNF, a Magic Bullet in Cancer Immunotherapy?” Journal for Immunotherapy of Cancer 7, no. 1 (November 14, 2019): 303. https://doi.org/10.1186/s40425-019-0802-y.
Dubot, Patricia, Frédérique Sabourdy, Jitka Rybova, Jeffrey A. Medin, and Thierry Levade. “Inherited Monogenic Defects of Ceramide Metabolism: Molecular Bases and Diagnoses.” Clinica Chimica Acta; International Journal of Clinical Chemistry 495 (August 2019): 457–66. https://doi.org/10.1016/j.cca.2019.05.020.
Baudoin-Dehoux, Cécile, Tessa Castellan, Frédéric Rodriguez, Arnaud Rives, Fabien Stauffert, Virginie Garcia, Thierry Levade, Philippe Compain, and Yves Génisson. “Selective Targeting of the Interconversion between Glucosylceramide and Ceramide by Scaffold Tailoring of Iminosugar Inhibitors.” Molecules (Basel, Switzerland) 24, no. 2 (January 19, 2019): 354. https://doi.org/10.3390/molecules24020354.
Alaeddine, Mohamad, Mélissa Prat, Véréna Hauke Poinsot, Valérie Gouazé-Andersson, Hélène Authier, Etienne Meunier, Lise Lefèvre, et al. “IL13-Mediated Dectin-1 and Mannose Receptor Overexpression Promotes Macrophage Antitumor Activities through Recognition of Sialylated Tumor Cells.” Cancer Immunology Research, January 4, 2019. https://doi.org/10.1158/2326-6066.CIR-18-0213.
Leclerc, Justine, David Garandeau, Charlotte Pandiani, Céline Gaudel, Karine Bille, Nicolas Nottet, Virginie Garcia, et al. “Lysosomal Acid Ceramidase ASAH1 Controls the Transition between Invasive and Proliferative Phenotype in Melanoma Cells.” Oncogene 38, no. 8 (2019): 1282–95. https://doi.org/10.1038/s41388-018-0500-0.
Garandeau, David, Justine Noujarède, Justine Leclerc, Caroline Imbert, Virginie Garcia, Marie-Lise Bats, Florian Rambow, et al. “Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas.” Molecular Cancer Therapeutics 18, no. 2 (2019): 289–300. https://doi.org/10.1158/1535-7163.MCT-17-1141.
Montfort, Anne, Céline Colacios, Thierry Levade, Nathalie Andrieu-Abadie, Nicolas Meyer, and Bruno Ségui. “Corrigendum: The TNF Paradox in Cancer Progression and Immunotherapy.” Frontiers in Immunology 10 (2019): 2515. https://doi.org/10.3389/fimmu.2019.02515.
Montfort, Anne, Céline Colacios, Thierry Levade, Nathalie Andrieu-Abadie, Nicolas Meyer, and Bruno Ségui. “The TNF Paradox in Cancer Progression and Immunotherapy.” Frontiers in Immunology 10 (2019): 1818. https://doi.org/10.3389/fimmu.2019.01818.
Bilal, Fatima, Anne Montfort, Julia Gilhodes, Virginie Garcia, Joëlle Riond, Stéphane Carpentier, Thomas Filleron, et al. “Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma.” Frontiers in Pharmacology 10 (2019): 443. https://doi.org/10.3389/fphar.2019.00443.
Team members
Partnerships & funding
Centre de Recherches en Cancérologie de Toulouse (Oncopole)
Toulouse – FR
CRCT-Oncopole Follow 1,434 1,195
Compte officiel du Centre de Recherches en Cancérologie de Toulouse
Prize for the best communication at the French Association for Pancreatic Cancer Research (AFRCP) day for @BousquetVaysse team at @crctoncopole
➡️
Nous contacter
05 82 74 15 75
Envie de rejoindre
L’équipe du CRCT ?
